Expression and secretion system
By introducing synthetic introns and mammalian signal sequences into nucleic acid molecules, the expression of Fab fragments in prokaryotic and eukaryotic cells was achieved, solving the problem of low Fab fragment reformatting efficiency in phage display antibody development and realizing efficient full-length IgG expression and purification.
Patent Information
- Application Number
- CN202411174185.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2013-05-03
- Filing Date
- 2013-07-03
- Publication Date
- 2024-11-26
AI Technical Summary
In the development of phage display antibodies, existing technologies are inefficient in reformatting the selected Fab fragments into full-length IgG, and require multiple cloning and screening processes, resulting in a low success rate.
The expression of Fab-phage fusion protein was driven in prokaryotic and eukaryotic cells using mammalian signal sequences. By introducing synthetic introns into nucleic acid molecules, host cell-dependent switching of Fab fragment display in phage and expression of full-length IgG in mammalian cells was achieved, avoiding the subcloning process.
This technology enables efficient selection of Fab fragments and direct expression and purification of full-length IgG, simplifying the antibody development process and improving success rate and efficiency.
Smart Images

Figure BDA0005010246450000141 
Figure BDA0005010246450000143 
Figure BDA0005010246450000331
Abstract
Description
[0001] This application is a divisional application of Chinese application No. 201910003915.0, whose application date is July 3, 2013 and whose invention name is “Expression and Secretion System”.
[0002] Cross-references to related applications
[0003] This application claims the benefit of priority to U.S. Provisional Application Nos. 61 / 668,397, filed on July 5, 2012, 61 / 852,483, filed on March 15, 2013, and 61 / 819,063, filed on May 3, 2013, all of which are incorporated herein by reference in their entirety. Field of the Invention
[0004] The present invention relates to expression and secretion systems and methods of their use, for expressing and secreting a Fab fusion protein when nucleic acid is transformed into prokaryotic cells for phage display, and expressing and secreting different or identical Fab fusion proteins when nucleic acid is transfected into eukaryotic cells for expression and purification. Also provided herein are nucleic acid molecules, vectors, and host cells comprising such vectors and nucleic acid molecules. Background of the Invention
[0006] Phage display of polypeptides or proteins on filamentous phage particles is an in vitro technique that allows the selection of peptides or proteins with desired properties from large libraries of diverse peptides or proteins (McCafferty et al., Nature , 348:552-554 (1990); Sidhu et al., Current Opinion in Biotechnology, 11:610-616 (2000); Smith et al., Science, 228:1315-1317 (1985). Phage display can be used to display different libraries of peptides or proteins (including antibody fragments such as Fab in the field of antibody research and development) on the surface of filamentous phage particles, and then select those that bind to a specific antigen of interest. Antibody fragments can be displayed on the surface of filamentous phage particles by fusing the gene for the antibody fragment with the gene for the phage coat protein, producing phage particles that display the encoded antibody fragment on their surface. This technology allows the isolation of antibody fragments with desired affinities for a variety of antigens from large phage libraries.
[0007] For phage-based antibody development, evaluating the properties of selected antibody fragments and their cognate IgG in functional assays (e.g., target binding, cell-based activity assays, in vivo half-life, etc.) requires reformatting the Fab heavy chain (HC) and light chain (LC) sequences into full-length IgG by isolating the DNA sequences encoding HC and LC from the vector used for phage display and subcloning into a mammalian expression vector for IgG expression. The laborious process of subcloning dozens or hundreds of selected HC / LC pairs represents the main bottleneck of phage-based antibody development methods. In addition, once reformatted, since a significant proportion of the selected Fabs did not perform satisfactorily in the initial screening assays, increasing the number of clones subjected to the reformatting / screening process will greatly increase the ultimate probability of success.
[0008] Herein, we describe the generation of an expression and secretion system for driving the expression of Fab-phage fusions when transformed into E. coli and for driving the expression of full-length IgG containing the same Fab fragments when transfected into mammalian cells. We demonstrate that mammalian signal sequences from mouse binding immunoglobulin (mBiP) (Haas et al., Immunoglobulin heavy chain binding protein, Nature, 306: 387-389 (1983); Munro et al., An Hsp70-like protein in the ER: identify with the 78kd glucose-regulated protein and immunoglobulin heavy chain binding protein, Cell, 4: 291-300 (1986)) can drive efficient protein expression in both prokaryotic and eukaryotic cells. Using mammalian mRNA splicing, removal of the signal sequence in human IgG 1 Using a synthetic intron containing a phage fusion peptide inserted within the hinge region of HC, we can produce two different proteins in a host cell-dependent manner: Fab fragments fused to a linker peptide for phage display in E. coli and native human IgG in mammalian cells. 1 This technology allows the selection of Fab fragments binding to the antigen of interest from a phage display library and the subsequent expression and purification of homologous full-length IgG in mammalian cells without the need for subcloning. SUMMARY OF THE INVENTION
[0010] In one aspect, the invention is based in part on the following experimental findings: (1) signal sequences of non-prokaryotic origin can function in prokaryotes and (2) different Fab fusion proteins (Fab-phage fusion proteins in prokaryotes and Fab-Fc fusion proteins in eukaryotic cells) can be expressed from the same nucleic acid molecule in a host cell-dependent manner when mRNA processing occurs in eukaryotic cells, but not in prokaryotes. Thus, described herein are nucleic acid molecules and methods of use that express and secrete in bacteria Fab fragments fused to phage particle proteins, coat proteins, or linker proteins for phage display when the nucleic acid is transformed into a prokaryotic host cell (e.g., E. coli), and Fab fragments fused to Fc when the nucleic acid is transformed into a eukaryotic cell (e.g., a mammalian cell) without the need for subcloning.
[0011] In one embodiment, the invention provides such a nucleic acid molecule, which encodes a first polypeptide comprising VH-HVR1, VH-HVR2 and HVR3 of a variable heavy chain domain (VH) and / or a second polypeptide comprising VL-HVR1, VL-HVR2 and VL-HVR3 of a variable light chain domain, and wherein the nucleic acid molecule also encodes a signal sequence that functions in both prokaryotic and eukaryotic cells, and which is encoded by a nucleic acid sequence effectively connected to the first and / or second polypeptide sequence, and wherein the full-length antibody is expressed from the first and / or second polypeptide of the nucleic acid molecule. In another embodiment, the first and / or second polypeptide also comprises a variable heavy chain (VH) domain and a variable light chain (VL) domain. In another embodiment, the VH domain is connected to CH1, and the VL domain is connected to CL.
[0012] In one aspect, the invention provides a nucleic acid molecule encoding VH-HVR1, VH-HVR2 and VH-HVR3 of a variable heavy chain domain (VH) and VL-HVR1, VL-HVR2 and VL-HVR3 of a variable light chain domain (VL), and comprising a prokaryotic promoter and a eukaryotic promoter, said promoter being operably linked to the HVR of VH and / or the HVR of VL to allow expression of the HVR of VH and the HVR of VL in prokaryotic and eukaryotic cells, and wherein when expressed by eukaryotic cells, the HVR of VH and / or VL is linked to a utility peptide, and wherein the nucleic acid further encodes a signal sequence that functions in both prokaryotic and eukaryotic cells.
[0013] In another aspect, the present invention provides a nucleic acid molecule encoding a variable heavy chain (VH) domain and a variable light chain (VL) domain, and comprising a prokaryotic promoter and a eukaryotic promoter, said promoter being operably linked to the VH domain and / or VL domain to allow expression of the VH domain and / or VL domain in prokaryotic and eukaryotic cells, and wherein when expressed by eukaryotic cells, the VH domain and / or VL is linked to a utility peptide, and wherein the nucleic acid further encodes a signal sequence that functions in both prokaryotic and eukaryotic cells.
[0014] In one embodiment, VL and VH are linked to a utility peptide. In another embodiment, VH is also linked to CH1, and VL is linked to CL. The utility peptide is selected from Fc, a tag, a marker, and a control protein. In one embodiment, VL is linked to a control protein, and VH is linked to Fc. For example, the control protein is a gD protein or a fragment thereof.
[0015] In even further embodiments, the first and / or second polypeptide of the invention is fused to a coat protein (e.g., pI, pII, pIII, pIV, pV, pVI, pVII, pVIII, pIX and pX of bacteriophage M13, f1 or fd, or a fragment thereof, such as amino acids 267-421 or 262-418 of the pIII protein (unless otherwise indicated, as used herein, "pI", "pII", "pIII", "pIV", "pV", "pVI", "pVII", "pVIII", "pIX" and "pX" refer to the full-length protein or a fragment thereof)), or a linker protein (e.g., a leucine zipper protein or a polypeptide comprising SEQ ID NO: 12 (cJUN(R): or SEQ ID NO: 13 (FosW (E): or a polypeptide comprising an amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 13) or a variant thereof (modified amino acids in SEQ ID NO: 12 and SEQ ID NO: 13, including but not limited to those amino acids indicated by underline and bold), wherein the variant has an amino acid modification, wherein the modification retains or increases the affinity of the adaptor protein for another adaptor protein or a polypeptide comprising an amino acid sequence selected from SEQ ID NO: 6 (ASIARLRERVKTLRARNYELRSRANMLRERVAQLGGC) or SEQ ID NO: 7 (ASLDELEAEIEQLEEENYALEKEIEDLEKELEKLGGC)), or a polypeptide comprising an amino acid sequence of SEQ ID NO: 8 (GABA-R1: EEKSRLLEKENRELEKIIAEKEERVSELRH QLQSVGGC) or SEQ ID NO: 9 (GABA-R2: TSRLEGLQSENHRLRMKITELDKDLEEVTMQLQDVGGC) or SEQ ID NO: 14 (Cys: AGSC) or SEQ ID NO: 15 (hinge: CPPCPG). The nucleic acid molecule encoding the coat protein or the adapter protein is contained in a synthetic intron. The synthetic intron is located between the nucleic acid encoding the VH domain and the nucleic acid encoding the Fc. The synthetic intron also includes a nucleic acid encoding a naturally occurring intron from IgG1, wherein the naturally occurring intron is selected from intron 1, intron 2 or intron 3 of IgG1.
[0016] In one embodiment, the invention provides such nucleic acid molecules, wherein in prokaryotic cells, the first fusion protein is expressed, and in eukaryotic cells, the second fusion protein is expressed.The first fusion protein and the second fusion protein can be identical or different.In other embodiments, the first fusion protein can be a Fab-phage fusion protein (for example comprising the Fab-phage fusion protein of the VH / CH1 fused with pill), and the second fusion protein can be a Fab-Fc or Fab-hinge-Fc fusion protein (for example comprising the Fab-Fc or Fab-hinge-Fc fusion protein of the VH / CH1 fused with Fc).
[0017] In one embodiment, the present invention provides a nucleic acid molecule wherein the signal sequence directs protein secretion to the endoplasmic reticulum or extracellularly in eukaryotic cells and / or wherein the signal sequence directs protein secretion to the periplasm or extracellularly in prokaryotic cells. In addition, nucleic acid sequences that can encode a signal sequence include nucleic acid sequences encoding an amino acid sequence comprising SEQ ID NO: 10 (XMKFTVVAAALLLLGAVRA), wherein X = 0 amino acids or 1 or 2 amino acids (e.g., X = M (SEQ ID NO: 3; MMKFTVVAAALLLLGAVRA; wild-type mBIP) or X = MT (SEQ ID NO: 19; MTMKFTVVAAALLLLGAVRA) or X is deleted (SEQ ID NO: 20; MKFTVVAAALLLLGAVRA) or a nucleic acid sequence encoding mBIP (SEQ ID NO: 4; ATG ATG AAA TTT ACC GTG GTG GCG GCG GCGCTG CTG CTG CTG GGC GCGGTC CGC GCG) and variants thereof, or a nucleic acid sequence encoding an amino acid sequence having at least 90% amino acid sequence identity to an amino acid sequence selected from SEQ ID NO: 3 (mBIP amino acid sequence), and wherein the signal sequence is functional in both prokaryotes and eukaryotes, or SEQ ID NO: 40; MKFTVVAAALLLLGAVRA; wild-type mBIP) or X = MT (SEQ ID NO: 19; MTMKFTVVAAALLLLGAVRA) or X is deleted (SEQ ID NO: 20; MKFTVVAAALLLLGAVRA) or a nucleic acid sequence encoding mBIP (SEQ ID NO: 4; ATG ATG AAA TTT ACC GTG GTG GCG GCG GCGCTG CTG CTG CTG GGC GCGGTC CGC GCG) and variants thereof. NO: 11 (consensus mBIP sequence, X ATG AAN TTNACN GTN GTNGCN GCN GCN CTN CTN CTN CTN GGN GCN GTN CGN GCN, wherein N=A, T, C or G, wherein X=ATG (SEQ ID NO: 5; ATG ATG AAN TTN ACN GTN GTN GCN GCNGCN CTN CTN CTN CTNGGN GCN GTN CGN GCN), X=ATG ACC (SEQ ID NO: 21; ATG ACC ATG AAN TTN ACN GTN GTNGCN GCN GCN CTN CTN CTN CTN GGNGCN GTN CGN GCN) or X=a nucleic acid sequence deleted (SEQ ID NO: 22; ATGAAN TTN ACN GTN GTNGCN GCN GCN CTN CTN CTN CTN GGN GCN GTN CGN GCN), or a nucleic acid sequence selected from
[0018] SEQ ID NO: 16 (mBIP.Opt1: ATG ATG AAA TTT ACCGTT GTT GCT GCT GCT CTG CTACTT CTT GGA GCG GTC CGC GCA), SEQ ID NO: 1 7 (mBIP.Opt2: ATG ATG AAA TTT ACT GTTGTT GCG GCT GCT CTT CTC CTT CTTGGA GCG GTC CGC GCA) and SEQ ID NO. Nucleic acid sequence of NO: 18 (mBIP.Opt3: ATG ATG AAA TTT ACTGTT GTC GCT GCT GCT CTT CTA CTT CTT GGA GCG GTC CGC GCA).
[0019] In another embodiment, the synthetic intron in the nucleic acid molecule is flanked by nucleic acid encoding CH1 at its 5' end and nucleic acid encoding Fc at its 3' end. In addition, the nucleic acid encoding the CH2 domain comprises a portion of a native splice donor sequence, and the nucleic acid encoding Fc comprises a portion of a native splice acceptor sequence. Alternatively, the nucleic acid encoding the CH2 domain comprises a portion of a modified splice donor sequence, wherein the modified splice donor sequence comprises a modification of at least one nucleic acid residue, and wherein the modification increases splicing.
[0020] In one embodiment, the prokaryotic promoter is phoA, Tac, Tphac or Lac promoter and / or the eukaryotic promoter is CMV or SV40 or Moloney murine leukemia virus U3 region or caprine arthritis encephalitis virus U3 region or sheep demyelinating leukoencephalitis virus U3 region or reverse transcriptase U3 region sequence. Expression by prokaryotic promoter occurs in bacterial cells, and expression by eukaryotic promoter occurs in mammalian cells. In other embodiments, the bacterial cell is Escherichia coli, and the eukaryotic cell is a yeast cell, a CHO cell, a 293 cell or a NSO cell.
[0021] In another embodiment, the invention provides a vector comprising a nucleic acid molecule as described herein and / or a host cell transformed with such a vector. The host cell can be a bacterial cell (e.g., an E. coli cell) or a eukaryotic cell (e.g., a yeast cell, a CHO cell, a 293 cell, or a NSO cell).
[0022] In another embodiment, the invention provides a method of producing an antibody, comprising culturing a host cell as described herein to allow expression of the nucleic acid. The method further comprises recovering the antibody expressed by the host cell, and wherein the antibody is recovered from the host cell culture medium.
[0023] In one aspect, the present invention provides a linker protein comprising at least one residue of an amino acid sequence of modified SEQ ID NO: 8, 9, 12, 13, 14 or 15. In one embodiment, the amino acid sequence is selected from SEQ ID NO: 6 (ASIARLRERVKTLRARNYELRSRANMLRERVAQLGGC) or SEQ ID NO: 7 (ASLDELEAEIEQLEEENYALEKEIEDLEKELEKLGGC). In one embodiment, the present invention provides a nucleic acid encoding such a linker protein.
[0024] In one aspect, the present invention provides nucleic acid molecules that function in both prokaryotic and eukaryotic cells, encoding mBIP polypeptides comprising the amino acid sequence of SEQ ID NO: 3 and variants thereof, or polypeptides having an amino acid sequence with 85% homology to the amino acid sequence of SEQ ID NO: 3. In one embodiment, the present invention provides methods for expressing mBIP polypeptides comprising the amino acid sequence of SEQ ID NO: 3 and variants thereof in both prokaryotic and eukaryotic cells. In one embodiment, the present invention provides bacterial cells that can express mBIP sequences comprising the amino acid sequence of SEQ ID NO: 3 and variants thereof.
[0025] In one aspect, the invention provides a synthetic intron located between a nucleic acid encoding a VH domain and a nucleic acid encoding an Fc or hinge of an antibody, between nucleic acids encoding the CH2 and CH3 domains of an antibody, or between nucleic acids encoding the hinge region and the CH2 domain of an antibody.
[0026] In one aspect, the present invention comprises a polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, a variable heavy chain domain (VH) and a variable light chain domain (VL), wherein the VH domain is linked to the amino terminus of the VL domain, or the polypeptide comprises a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, a variable heavy chain domain (VH) and a variable light chain domain (VL), wherein the VH domain is linked to the carboxyl terminus of the VL domain, or the polypeptide comprises a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 and VH-HVR1, VH-HVR2 and VH-HVR3 of the variable heavy chain domain (VH), or the polypeptide comprises a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 and VL-HVR1, VL-HVR2 and VL-HVR3 of the variable light chain domain (VL), or the polypeptide comprises a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 and VL-HVR1, VL-HVR2 and VL-HVR3 of the variable light chain domain (VL), or the polypeptide comprises a NO:3 amino acid sequence or its variant, VH-HVR1, VH-HVR2 and VH-HVR3 of variable heavy chain domain (VH) and VL-HVR1, VL-HVR2 and VL-HVR3 of variable light chain domain (VL). In one embodiment, the polypeptide of the present invention is an antibody or antibody fragment. The antibody or antibody fragment of the present invention can be selected from F(ab')2 and Fv fragments, double antibodies and single-chain antibody molecules.
[0027] In one aspect, the invention includes a mutated helper phage for enhancing phage display of proteins. In one embodiment, the nucleotide sequence of the helper phage comprises an amber mutation in pill, wherein the helper phage comprising the amber mutation enhances display of proteins fused to pill on phage. In a further embodiment, in the nucleotide sequence of claim 70, the amber mutation is a mutation in nucleotides 2613, 2614, and 2616 of the M13KO7 nucleic acid. In even further embodiments, the nucleotide sequence of claim 71, wherein the mutation in nucleotides 2613, 2614, and 2616 of the M13KO7 nucleic acid introduces an amber stop codon. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1. (A) Her2 phage ELISA of purified phage displaying anti-Her2 Fab under the control of 4 different eukaryotic signal sequences (mBiP, Gaussia princeps, yBGL2, hGH). The heat stable enterotoxin II (STII) prokaryotic signal sequence commonly used in phagemids was used as a benchmark. (B) Phage display of anti-Her2 Fab fused to the wild-type eukaryotic mBiP signal sequence (mBiP.wt), and codon optimized versions obtained by phage library panning (mBiP.Opt1, mBiP.Opt2 and mBiP.Opt3 (SEQ ID NOs: 16-18)).
[0030] Figure 2. (A) Expression yields from 30 mL 293 cell suspension cultures of individual clones and (B) aggregate statistics analysis of hIgG1 clones expressed as fusions with eukaryotic mBiP or prokaryotic native IgG HC (VHS) signal sequences.
[0031] Figure 3. (A) Genomic structure of human IgG1 HC containing three natural introns. Intron 1 occurs immediately before the hinge region. (B) HC construct containing a synthetic intron derived from intron 1 or 3 and containing a phage linker fusion peptide. The synthetic intron is flanked by natural intron splice donors (D) and acceptors (A) from intron 1 or 3. (C) HC construct containing a synthetic intron derived from intron 1 or 3 and containing a phage coat fusion protein. The synthetic intron is flanked by natural intron splice donors (D) and acceptors (A) from intron 1 or 3. Both constructs (B) and (C) contain a STOP codon at the 3' end of the linker peptide or phage coat protein sequence.
[0032] Figure 4. (A) Synthetic intron from intron-free, phage linker peptide (see Figure 3B ) or containing phage coat protein (gene-III, see Figure 3C (A) Expression levels of h4D5 IgG in constructs containing synthetic introns. (B) RT-PCR of hIgG1 HC from transfected cells. The predicted size of correctly spliced HC mRNA is 1,650 nt. The upper band in the linker+intron 1 construct represents unspliced pre-mRNA. The lower band in the linker- and gene-III-containing construct is incorrectly spliced in VH by a cryptic splice donor.
[0033] Figure 5. (A) Point mutations generated in the native intron 1 splice donor to increase consensus splice donor identity for mammalian mRNAs. (B) Optimization of the intronic splice donor eliminates accumulation of unspliced and improperly spliced HC mRNA and (C) increases expression in mammalian cells to levels observed in the absence of the intron.
[0034] Figure 6. (A) Modulated display using pDV.5.0 and wild-type KO7 (monovalent display) or linker KO7 (multivalent display). (B) Expression of four different mAbs from pDV.5.0 in three different mammalian cell lines.
[0035] Figure 7 Schematic diagram of vectors for expression and secretion of polypeptides in prokaryotic and eukaryotic cells. Synthetic introns can contain linker sequences or phage coat proteins, as well as any naturally occurring intron sequence from hIgG1. Both HC and LC can have: 1) mammalian and bacterial promoters upstream of the ORF, 2) only bacterial promoters upstream of the ORF (see also Fig.14 ) or 3) only mammalian promoter upstream of the ORF. Constructs are shown where both the HC and LC have both promoter types. Constructs containing gene-III with a linker peptide fusion (shown in pDV5.0) are only present when the synthetic intron contains the linker peptide fusion, but not when the phage coat protein fusion is present in the synthetic intron.
[0036] Figure 8 .The nucleotide sequence of pill of helper phage Amber KO7 (nucleotides 1579 to 2853 (SEQ ID NO:24)) was mutated to enhance the display of proteins fused to pill on M13 phage. Amber KO7 has an amber codon introduced by site-directed mutagenesis in the M13KO7 helper phage genome. The underlined residues are mutations in nucleotides 2613, 2614, and 2616 (T2613C, C2614T, and A2616G) that introduce an amber stop (TAG) in codon 346 of gene III of M13KO7, and a silent mutation that introduces an AvrII restriction site in codon 345. Nucleotide 1 of M13KO7 is the third residue of a unique HpaI restriction site.
[0037] Fig. 9. Enhanced display of Fab fragments on pill of M13 phage by using Amber KO7 helper phage. When wild-type M13KO7 was used for phage production, conventional high display phagemids with wild-type M13KO7 (open diamonds) drove significantly higher Fab display levels than those achieved by low display phagemid vectors (closed squares). The use of modified M13KO7 carrying an amber mutation in pill (Amber KO7) increased the display levels of low display phagemids (closed triangles) to those of high display phagemids with wild-type M13KO7 (open diamonds).
[0038] Fig.10 . is a bar graph showing binding (measured by phage ELISA) against immobilized VEGF of clones selected from the natural dual-carrier Fab-phage library of phage library sorting Example 5. After four rounds of selection, individual clones were picked and phage supernatants were tested for binding to immobilized antigen (VEGF) and to an irrelevant protein (Her2) to evaluate binding specificity.
[0039] Fig.11 Shown are selected phage clones screened by BIAcore in IgG format for antigen binding to VEGF as measured by Fc capture assay on a BIAcore T100 instrument. 96 clones selected for sequencing analysis and phage ELISA were transfected into 293S cells (1 mL) and cultured for 7 days for IgG expression. The supernatant was filtered through 0.2 μm and used to evaluate VEGF antigen binding by Fc capture assay on a BIAcore T100 instrument.
[0040] Fig.12 Shown are the sequences of positive binders from the VEGF panning experiment in Example 5. Shown are the heavy chain CDR sequences of eight clones: VEGF50 (SEQ ID NOS 25-27, respectively, in order of appearance), VEGF51 (SEQ ID NOS 28-30, respectively, in order of appearance), VEGF52 (SEQ ID NOS 31-33, respectively, in order of appearance), VEGF59 (SEQ ID NOS 34-36, respectively, in order of appearance), VEGF55 (SEQ ID NOS 37-39, respectively, in order of appearance), VEGF60 (SEQ ID NOS 40-42, respectively, in order of appearance), VEGF61 (SEQ ID NOS 43-45, respectively, in order of appearance), and VEGF64 (SEQ ID NOS 46-48, respectively, in order of appearance). All clones shared identical light chain CDR sequences.
[0041] Fig.13 The ability of selected anti-VEGF IgGs selected from phage sorting against VEGF to inhibit the binding of VEGF to one of its natural receptors, VEGF-R1, is shown. Selected antibodies from sorting against VEGF were expressed in CHO and purified IgG was used to measure the ability of selected clones to inhibit the binding of VEGF to VEGF-R1. One clone (VEGF55) inhibited VEGF-R1 binding with an IC50 3.5 times that of bevacizumab (Avastin).
[0042] Fig.14 Schematic diagram of a vector for expression and secretion of polypeptides in prokaryotic and eukaryotic cells is shown, wherein the synthetic intron contains pill, and any naturally occurring intron sequence from hIgG1, and wherein the LC has a bacterial promoter upstream of the ORF, and the HC has both mammalian and bacterial promoters upstream of the ORF. Figure 7 The vector shown in , which vector (pDV6.5) does not require an additional gIII cassette for fusion with phage particles. The proteins produced from expression in E. coli and mammalian cells are shown in the vector schematic below. The dashed lines represent introns in the heavy chain transcript that are spliced in mammalian cells. It should be noted that the sequence portion encoding the IgG1 hinge is repeated in this vector to allow inclusion in proteins expressed by E. coli and mammalian cells.
[0043] Fig.15 The properties of full-length anti-VEGF IgG expressed from pDV6.5 are shown. IgG was expressed in 100 mL transfected CHO cell cultures and purified by protein A chromatography. The final yield of purified IgG is shown, as well as the score in the baculovirus ELISA for measuring non-specific binding. Positive or negative binding of each clone in phage format (phage ELISA) or IgG format (BIAcore) is also shown.
[0044] DETAILED DESCRIPTION OF EMBODIMENTS OF THE INVENTION
[0045] I. Definitions
[0046] In this article, the term "synthetic intron" is used to define a nucleic acid segment between a nucleic acid encoding CH1 and a nucleic acid encoding hinge-Fc or Fc."Synthetic intron" can be any nucleic acid that does not encode protein synthesis, any nucleic acid encoding protein synthesis (e.g., phage particle protein or coat protein (e.g., pI, pII, pIII, pIV, pV, pVI, pVII, pVIII, pIX, pX) or a linker protein (e.g., leucine zipper, etc.)) or a combination thereof. In one embodiment, a "synthetic intron" comprises a portion of a splicing donor sequence and a splicing acceptor sequence that allow splicing events. Splicing donor and splicing acceptor sequences allow splicing events and can comprise natural or synthetic nucleic acid sequences.
[0047] In this article, the term "utility polypeptide" is used to refer to a polypeptide used for several activities, such as protein purification, protein tagging, protein labeling (e.g., labeling with a detectable compound or composition (e.g., radiolabeling, fluorescent labeling, or enzyme labeling)). The label can be indirectly conjugated to an amino acid side chain, an activated amino acid side chain, an antibody with a cysteine engineered, etc. For example, the antibody can be conjugated to biotin, and one of the above three major types of labels can be conjugated to avidin or streptavidin, or vice versa. Biotin selectively binds to streptavidin, and thus the label can be conjugated to the antibody in this indirect manner. Alternatively, in order to achieve indirect conjugation of the label to the polypeptide variant, the polypeptide variant is conjugated to a small hapten (e.g., digoxin), and one of the above different types of labels is conjugated to an anti-hapten polypeptide variant (e.g., anti-digoxin antibody). Thus, indirect conjugation of the label to the polypeptide variant is achieved (Hermanson, G. (1996) in Bioconjugate Techniques Academic Press, San Diego).
[0048] When a nucleic acid is placed in a functional relationship with another nucleic acid sequence, it is "operably connected". For example, if the DNA for the presequence or secretory leader sequence is expressed as a preprotein that participates in the secretion of a polypeptide, it is effectively connected to the DNA for the polypeptide; if a promoter or enhancer affects the transcription of the sequence, it is effectively connected to the coding sequence; if the ribosome binding site is located at a position that can assist translation, it is effectively connected to the coding sequence. In short, "operably connected" means that the DNA sequences connected are present in a nucleic acid molecule, so that they can have a functional relationship with each other as nucleic acids or with proteins expressed by them. They can be continuous or discontinuous. In the case of a secretory leader sequence, they are generally continuous and in the reading phase. However, enhancers do not have to be continuous. Connection can be achieved by ligation at a suitable restriction site. If there is no such site, a synthetic oligonucleotide linker or connector can be used.
[0049] When a nucleic acid encoding a heterologous protein sequence (e.g., a VH or VL region) is directly inserted into a nucleic acid encoding a phage coat protein (e.g., pII, pVI, pVII, pVIII, or pIX), the VH or VL domain is "linked" to the phage. When introduced into a prokaryotic cell, a phage can be produced in which the coat protein can display the VH or VL domain. In one embodiment, the resulting phage particle displays an antibody fragment fused to the amino or carboxyl terminus of the phage coat protein.
[0050] As used herein, the term "connected" or "connected" is intended to mean that two amino acid sequences or two nucleic acid sequences are covalently bound together by a peptide bond or a phosphodiester bond, respectively, and the binding may include any number of other amino acids or nucleic acid sequences between the two bound amino acid sequences or nucleic acid sequences. For example, the first and second amino acid sequences may be directly peptide-linked or there may be a connection of one or more amino acid sequences between the first and second amino acid sequences.
[0051] As used herein, "connector" means an amino acid sequence of two or more amino acids in length. The connector can be composed of neutral polar or non-polar amino acids. The connector can be, for example, 2-100 amino acids in length, for example, a length between 2 and 50 amino acids, for example, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acids in length. The connector can be "cleavable", for example, by self-cleavage or enzymatic or chemical cleavage. The cleavage site in the amino acid sequence and the enzyme or chemical substance that cuts at the site are well known in the art and are also described herein.
[0052] The term "signal sequence function" refers to the biological activity of the signal sequence directing the secretion of a protein into the ER (in eukaryotes) or the periplasm (in prokaryotes) or outside the cell.
[0053] As used herein, "control protein" refers to a protein sequence whose expression is measured to quantify the display level of the protein sequence. For example, the protein sequence can be an "epitope tag" that can be easily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Examples of tag polypeptides and their suitable respective antibodies include: poly-histidine (poly-His) or poly-histidine-glycine (poly-His-gly) tags; influenza HA tag polypeptide and its antibody 12CA5 [Field et al., Mol.Cell.Biol. , 8 :2159-2165 (1988)]; c-myc tag and 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies [Evan et al., Molecular and Cellular Biology , 5 : 3610-3616 (1985)]; and herpes simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering , 3(6) :547-553 (1990)]. Other tag polypeptides include Fiag-peptide [Hopp et al., BioTechnology , 6 :1204-1210 (1988)]; KT3 epitope peptide [Martin et al., Science , 255 :192-194 (1992)]; α-tubulin epitope peptide [Skinner et al., J.Biol.Chem. , 266 :15163-15166 (1991)]; and T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc.Natl.Acad.Sci.USA , 87 :6393-6397(1990)].
[0054] As used herein, "coat protein" refers to one of the five capsid proteins that make up the phage particle, including pill, pVI, pVII, pVIII and pIX. In one embodiment, "coat protein" can be used to display proteins or peptides (see Phage Display, A Practical Approach, Oxford University Press, edited by Clackson and Lowman, 2004, p.1-26). In one embodiment, the coat protein can be pill protein or some variants, a part and / or derivatives thereof. For example, the carboxyl terminal portion (cP3) of the M13 phage pill coat protein can be used, such as the sequence encoding the carboxyl terminal residues 267-421 of the protein III of the M13 phage. In one embodiment, the pill sequence comprises SEQ ID NO: 1:
[0055] In one embodiment, the pIII fragment comprises the amino acid sequence of SEQ ID NO: 2
[0056] The amino acid sequence of
[0057] As used herein, "connector protein" refers to a protein sequence that specifically interacts with another connector protein sequence in solution. In one embodiment, the "connector protein" comprises a heterotypic multimerization domain. In one embodiment, the connector protein is a cJUN protein or a Fos protein. In another embodiment, the connector protein comprises a sequence of SEQ ID NO: 6 (ASIARLRERVKTLRARNYELRSRANMLRERVAQLGGC) or SEQ ID NO: 7 (ASLDELEAEIEQLEEENYALEKEIEDLEKELEKLGGC).
[0058] As used herein, "heteromeric multimerization domain" refers to a change or addition to a biomolecule that promotes heteromeric formation and discourages homomeric formation. Any heteromeric multimerization domain that has a strong preference for forming heterodimers over homodimers is within the scope of the present invention. Illustrative examples include, but are not limited to, for example, U.S. Patent Application 20030078385 (Arathoon et al. - Genentech; describes knob into holes); WO2007147901 ( et al. - Novo Nordisk: describes ionic interactions); WO 2009089004 (Kannan et al. - Amgen: describes electrostatic steering effects); WO201 1 / 034605 (Christensen et al. - Genentech; describes coiled coils). See also, Pack, P. & Plueckthun, A., Biochemistry 31, 1579-1584 (1992) describing leucine zippers or Pack et al., Bio / Technology 11, 1271-1277 (1993) describing helix-turn-helix motifs. The phrases "heteromeric multimerization domain" and "heterodimerization domain" are used interchangeably herein.
[0059] As used herein, the term "Fab-fusion protein" refers to Fab-phage fusion proteins in prokaryotes and / or Fab-Fc fusion proteins in eukaryotic cells. The Fab-Fc fusion can also be a Fab-hinge-Fc fusion.
[0060] Herein, the term "antibody" is used in its broad sense and includes various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (eg, bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.
[0061] "Antibody fragment" refers to a molecule that is different from an intact antibody and contains a portion of an intact antibody, which binds to the antigen bound by the intact antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'--SH, F(ab') 2 ; diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
[0062] The "class" of an antibody refers to the type of constant domain or region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of them can be further divided into subclasses (isotypes), such as IgG. 1 IgG 2 IgG 3 IgG 4 , IgA 1 and IgA 2 The heavy chain constant regions corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0063] In this article, the term "Fc region" is used to define the carboxyl terminal region of the immunoglobulin heavy chain containing at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl end of the heavy chain. However, the carboxyl terminal lysine (Lys447) of the Fc region may or may not exist. Unless otherwise indicated herein, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991, according to the EU coding system, also referred to as the EU index, the amino acid residues in the Fc region or constant region are numbered.
[0064] "Framework" or "FR" refers to variable region residues other than hypervariable region (HVR) residues. The FR of a variable region is typically composed of four FR regions: FR1, FR2, FR3, and FR4. Thus, in VH (or VL), HVR and FR sequences typically appear in the following sequence: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
[0065] The terms "full length antibody," "intact antibody," and "whole antibody" used interchangeably herein refer to antibodies having a structure substantially similar to a native antibody structure or having heavy chains comprising an Fc region as defined herein.
[0066] The terms "host cell", "host cell line" and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells", which include the original transformed cell and its derived progeny (regardless of the number of passages). Progeny may not be completely identical to the parent cell in terms of nucleic acid content, but may contain mutations. Mutant progeny having the same function or biological activity as the screened or selected original transformed cell are included herein.
[0067] As used herein, the term "hypervariable region" or "HVR" refers to each region of an antibody variable region that is hypervariable in sequence and / or forms a structurally defined loop ("hypervariable loop"). Typically, a natural four-chain antibody comprises six HVRs; three in VH (H1, H2, H3) and three in VL (L1, L2, L3). HVRs typically comprise amino acid residues from hypervariable loops and / or from "complementarity determining regions" (CDRs), which have the highest sequence variability and / or are involved in antigen recognition. Exemplary hypervariable loops are present in amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3). Chothia and Lesk, J. Mol. Biol. 196: 901-917 (1987). Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) are present in amino acid residues 24-34 of L1, 50-56 of L2, 89-97 of L3, 31-35 of H1, 50-65 of H2, and 95-102 of H3. (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).) Except for CDR1 in VH, CDRs generally include amino acid residues that form hypervariable loops. CDRs also include "specificity determining residues" or "SDRs," which are residues that contact antigen. SDRs are contained within the region of CDRs, referred to as "abbreviated-CDRs" or a-CDRs. Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) are present in amino acid residues 31-34 of L1, 50-55 of L2, 89-96 of L3, 31-35B of H1, 50-58 of H2, and 95-102 of H3. (See Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008).) Unless otherwise indicated, HVR residues, as well as other residues in the variable region (e.g., FR residues), are numbered herein according to Kabat et al., supra.
[0068] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.
[0069] An "isolated" antibody is one that has been separated from a component of its natural environment. In some embodiments, the antibody is purified to a purity of more than 95% or 99%, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).
[0070] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that normally contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0071] "Isolated nucleic acid encoding an antibody" refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecules in a single vector or separate vectors, as well as such nucleic acid molecules present at one or more locations in a host cell.
[0072] As used herein, the term "monoclonal antibody" refers to an antibody obtained from a substantially uniform antibody population, i.e., except for possible variant antibodies (e.g., variant antibodies containing naturally occurring mutations or occurring during the production of monoclonal antibody preparations, such variant antibodies are usually present in a smaller amount), each antibody contained in the population is identical and / or binds to the same epitope. Contrary to polyclonal antibody preparations (which usually include different antibodies directed to different determinants (epitopes)), each monoclonal antibody of a monoclonal antibody preparation is directly directed to a single determinant on an antigen. Therefore, the modifier "monoclonal" refers to the characteristics of an antibody obtained from a substantially uniform antibody population, and should not be construed as requiring the antibody to be produced by any particular method. For example, the monoclonal antibody used according to the present invention can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage-display methods, and methods using transgenic animals containing all or part of human immunoglobulin loci, such methods and other exemplary methods for preparing polyclonal antibodies are described herein.
[0073] A "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (eg, a cytotoxic moiety) or a radiolabel. Naked antibodies can be present in pharmaceutical formulations.
[0074] "Native antibodies" refer to naturally occurring immunoglobulin molecules with variable structures. For example, a natural IgG antibody is a heterotetrameric glycoprotein of about 150,000 daltons, which consists of two identical light chains and two identical heavy chains bonded by disulfide bonds. From the amino terminus to the carboxyl terminus, each heavy chain has a variable region (VH), also referred to as a variable heavy chain domain or a heavy chain variable region, followed by three constant domains (CH1, CH2, and CH3). Similarly. From the amino terminus to the carboxyl terminus, each light chain has a variable region (VL), also referred to as a variable light chain domain or a light chain variable domain, followed by a constant light chain (CL) domain. Based on the amino acid sequence of its constant domain, the light chain of an antibody can be designated as one of two types (called κ and λ).
[0075] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of that therapeutic product.
[0076] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains (VH and VL, respectively) of native antibodies generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs) (see, e.g., Kindt et al., Kuby Immunology, 6 th ed., WH Freeman and Co., page 91 (2007). ). A single VH or VL domain is sufficient to confer antigen binding specificity. In addition, VH and VL domains from antibodies that bind to antigens can be used to screen libraries of complementary VL or VH domains, respectively, to isolate antibodies that bind to specific antigens. See, e.g., Portolano et al., J. Immunol. 150: 880-887 (1993); Clarkson et al., Nature 352: 624-628 (1991).
[0077] As used herein, the term "vector" refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures, as well as vectors that are incorporated into the genome of a host cell into which they have been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors."
[0078] II. Detailed description
[0079] Phage-based antibody discovery methods use phage display technology to select Fab fragments with desired binding specificity from large libraries of individual phage particles. 1-3In this method, established molecular biology techniques and specific phage display vectors are used to generate phage libraries consisting of Fab fragments fused directly or indirectly through one of the major coat proteins to M13 filamentous phage particles and containing varying complementarity determining regions (CDRs) (Tohidkia et al., 2001). Journal of drug targeting , 20:195-208(2012); Bradbury et al., Nature biotechnology ,29:245-254(2011); Qi et al., Journal of molecular biology, 417:129-143 (2012)). Although the theoretical diversity of the library can easily exceed 10 25 unique sequences for a given library, but practical limitations of phage library construction usually limit the actual diversity to ≤ 10 11 clones (Sidhu et al., Methods in enzymology ,328:333-363(2000)).
[0080] Assuming that the starting library can contain a basic number of unique sequences, the screening throughput of the selected clones is very important. For phage-based antibody development, the characteristics of the selected Fab and its homologous full-length IgG are thoroughly evaluated in functional assays (target binding, cell-based activity assays, in vivo half-life, etc.), and the Fab heavy chain (HC) and light chain (LC) sequences need to be reformatted into full-length IgG by separating the DNA sequences encoding HC and LC from the phagemid vector used for display and subcloning into a mammalian expression vector for IgG expression. The laborious method of subcloning dozens or hundreds of selected HC / LC pairs represents the main bottleneck of the phage-based antibody development method. In addition, once reformatted, since a considerable proportion of the selected Fabs were not satisfactorily implemented in the initial screening assay, increasing the number of clones for the reformatting / screening method will greatly increase the ultimate probability of success.
[0081] Herein, we describe the generation of an expression and secretion system for expressing and secreting one Fab fusion protein in prokaryotes and a different (or the same) Fab fusion protein in eukaryotic cells. For example, the expression and secretion system drives the expression of a Fab-phage fusion when transformed into E. coli and drives the expression of a full-length IgG containing the same Fab fragment when transfected into mammalian cells. We demonstrate that the expression of a Fab-phage fusion protein from murine binding immunoglobulin (mBiP) 8,9 The mammalian signal sequence can drive efficient protein expression in both prokaryotic and eukaryotic cells. 1By inserting a synthetic intron containing a phage fusion peptide into the hinge region of HC, we can produce two different proteins in a host cell-dependent manner: Fab fragments fused to a linker peptide for phage display in E. coli and native human IgG in mammalian cells. 1 This technology allows the selection of Fab fragments that bind to the antigen of interest from a phage display library and the subsequent expression and purification of homologous full-length IgG in mammalian cells without the need for subcloning.
[0082] The present invention is based in part on the following experimental findings: (1) signal sequences of non-bacterial origin can function in prokaryotes at levels sufficient for sorting phage libraries without impairing IgG expression in eukaryotic cells and (2) different Fab fusion proteins (Fab-phage fusion proteins in prokaryotes and Fab-Fc fusion proteins in eukaryotic cells) can be expressed from the same nucleic acid molecule in a host cell-dependent manner when mRNA processing occurs in eukaryotic cells, rather than prokaryotes. Thus, described herein are expression and secretion systems and methods related to the construction and use of expression and secretion systems for expressing and secreting Fab fragments fused to phage particle proteins, coat proteins or linker proteins for phage display (in prokaryotic host cells (e.g., E. coli)) and Fab fragments fused to Fc (in eukaryotic cells (e.g., mammalian cells) without the need for subcloning. In particular, described herein are vectors for expressing and secreting Fab-phage fusion proteins in prokaryotic cells and Fab-Fc fusion proteins in eukaryotic cells, nucleic acid molecules for expressing and secreting proteins or peptides in prokaryotic and eukaryotic cells, and host cells comprising such vectors. In addition, described herein are methods for using the expression and secretion systems, including methods for using the expression and secretion systems for screening and selecting new antibodies against target proteins.
[0083] Mode for Carrying Out the Invention
[0084] The practice of the present invention may employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are fully described in the literature, for example, in "Molecular Cloning: A Laboratory Manual", Second Edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (MJ Gait, ed., 1984); "Animal Cell Culture" (RI Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology", Fourth Edition (DM Weir & C.C. Blackwell, eds., Blackwell Science Inc., 1987); "Gene Transfer Vectors for Mammalian Cells" (JM Miller & M.P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (FM Ausubel et al., eds., 1987); "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994); and "Current Protocols in Immunology”(JE Coligan et al., eds., 1991).
[0085] Expression and secretion systems for prokaryotic and eukaryotic cells
[0086] The expression and secretion system for prokaryotic and eukaryotic cells involves a vector containing regulatory and coding sequences for a protein of interest (e.g., a heavy chain or light chain of an IgG molecule), wherein prokaryotic and eukaryotic promoters (e.g., CMV (eukaryotic) and PhoA (prokaryotic)) are arranged in tandem upstream of the gene of interest, and a single signal sequence drives the expression of the protein of interest in prokaryotic and eukaryotic cells. The present invention provides a means for the vector to produce two different fusion forms of the protein of interest in a host cell-dependent manner by using a synthetic intron located between the VH / CH1 and hinge-Fc regions of IgG1.
[0087] A. Signal sequences that function in prokaryotes and eukaryotes
[0088] One challenge in constructing vectors that can express a protein of interest in both prokaryotic (E. coli) and eukaryotic (mammalian) cells arises from the differences in signal sequences found in these cell types. Although certain features of signal sequences are widely conserved in prokaryotic and eukaryotic cells (e.g., a small number of hydrophobic residues are located in the middle of the sequence, and polar / charged residues are adjacent to the cleavage site at the amino terminus of the mature polypeptide), other features are mostly different between different cell types. In addition, it is known in the art that different signal sequences have a significant effect on expression levels in mammalian cells, even if the sequences are of mammalian origin (Hall et al., J of Biological Sciences). Chemistry, 265:19996-19999 (1990); Humphreys et al., Protein Expression and Purification, 20:252-264 (2000). For example, bacterial cell sequences often have a positively charged residue (most commonly lysine) immediately following the initiator methionine, which is not typically found in mammalian signal sequences. Although there are known signal sequences that direct secretion in both cell types, such signal sequences typically direct high levels of protein secretion in only one cell type or the other.
[0089] Although bacterial signal sequences have rarely been shown to exhibit any function in mammalian cells, it has been reported that signal sequences of mammalian origin can drive transport into the bacterial periplasm (Humphreys et al., The Protein Expression and Purification, 20:252-264 (2000)). However, it is not sufficient for a signal sequence to simply be functional for a strong dual expression system of phage display and IgG expression. Instead, the selected signal sequence must be functional in both expression systems, particularly for phage display, where low levels of display may impair the system's ability to perform phage panning experiments.
[0090] The present invention is based in part on the discovery that signal sequences of non-bacterial origin can function in prokaryotes at levels sufficient for phage library sorting without impairing IgG expression in eukaryotic cells.
[0091] The present invention provides any signal sequence (including consensus signal sequences) that can be used to target the polypeptide of interest to the periplasm in prokaryotes and to the endoplasmic / reticulum in eukaryotic cells. Signal sequences that can be used include, but are not limited to, the mouse binding immunoglobulin (mBiP) signal sequence (UniProtKB: accession P20029), the signal sequence from human growth hormone (hGH) (UniProtKB: accession BIA4G6), Gaussia princeps luciferase (UniProtKB: accession Q9BLZ2), yeast endo-1,3-glucanase (yBGL2) (UniProtKB: accession P15703). In one embodiment, the signal sequence is a natural or synthetic signal sequence. In another embodiment, the synthetic signal sequence is an optimized signal secretion sequence that drives the level of display at an optimized level compared to its unoptimized natural signal sequence.
[0092] As described herein, suitable assays for determining the ability of a signal sequence to drive display of a polypeptide of interest in prokaryotic cells include, for example, phage ELISA.
[0093] As described herein, suitable assays for determining the ability of a signal sequence to drive expression of a polypeptide of interest in eukaryotic cells include, for example, transfecting a mammalian expression vector encoding a polypeptide of interest with a signal of interest into cultured mammalian cells, culturing the cells for a period of time, collecting the supernatant from the cultured cells, and purifying IgG from the supernatant by affinity chromatography.
[0094] B. Synthetic introns leading to expression of host-dependent fusion proteins from the same nucleic acid
[0095] The present invention is based in part on the discovery that different Fab-fusion proteins can be expressed from the same nucleic acid molecule in a host cell dependent manner by exploiting the natural process of intron splicing that occurs during mRNA processing in eukaryotic cells rather than in prokaryotes.
[0096] The genomic sequence of the hIgG1 HC constant region contains three natural introns ( Figure 3A ), intron 1, intron 2, and intron 3. Intron 1 is a 391 base pair intron located between the HC variable domain / CH1 (VH / CH1) and the hinge region. Intron 2 is a 118 base pair intron located between the hinge region and CH2. Intron 3 is a 97 base pair intron located between CH2 and CH3.
[0097] The present invention provides vectors comprising intron 1 located between VH / CH1 and the hinge region. Other examples include intron 2 or intron 3 located between VH / CH1 and the hinge region. For some vectors, nucleic acid encoding a coat protein or a linker protein is inserted into an intron located between VH / CH1 and the hinge region, with a natural splice donor for the intron at its 5' end and a natural splice acceptor at its 3' end.
[0098] Other examples include splice donors with mutations having substitutions at positions 1 and 5 in addition to position 8 of the splice donor.
[0099] For example, ELISA can be used to analyze expression and secretion systems in prokaryotic cells.
[0100] For example, IgG purified from culture supernatants using protein A and gel filtration chromatography can be used to analyze expression and secretion systems in eukaryotic cells.
[0101] C. Vectors for Expression and Secretion of Polypeptides in Prokaryotic and Eukaryotic Cells
[0102] Expression and secretion systems for expression and secretion of Fab-fusion proteins in prokaryotic and eukaryotic cells can be constructed using a variety of techniques within the skill in the art.
[0103] In one aspect, the expression and secretion system comprises a vector comprising: (1) a mammalian promoter; (2) an LC cassette comprising (in order from 5' to 3') a bacterial promoter, a signal sequence, an antibody light chain sequence, a control protein (gD); (3) a synthetic cassette comprising (in order from 5' to 3') a mammalian polyadenylation / transcription termination signal, a transcription terminator sequence for terminating transcription in prokaryotes, a mammalian promoter and a bacterial promoter for driving HC expression; (4) an HC cassette comprising a signal sequence and an antibody heavy chain sequence; and (5) a second synthetic cassette comprising a mammalian polyadenylation / transcription termination signal and a transcription terminator sequence for terminating transcription in prokaryotes. The secretory signal sequence preceding the LC and HC can be the same signal sequence that functions in both prokaryotes and eukaryotic cells (e.g., a mammalian mBiP signal sequence). In one embodiment, the antibody heavy chain sequence comprises a synthetic intron. The synthetic intron is located between the VH / CH1 domain (at its 5' end) and the hinge region (at its 3' end). In one embodiment, the synthetic intron is flanked by an optimized splice donor sequence at the 5' end and a native intron 1 splice acceptor sequence at the 3' end. In one embodiment, the synthetic intron comprises a nucleotide sequence encoding a bacteriophage coat protein (e.g., pill) for direct fusion display (see Fig.14 ), or encodes an adaptor protein fused to intron 1 at the nucleotide level for indirect fusion display (see Figure 7For indirect fusion display, the vector also comprises a separate bacterial expression cassette comprising (in order from 5' to 3') a bacterial promoter, a bacterial signal sequence, a bacteriophage coat protein (e.g., pill) having a partner linker peptide fused to the amino terminus of the coat protein at the nucleotide level, and a transcription terminator sequence (see Figure 7 ). In addition, different embodiments of the above constructs are possible, wherein the HC and LC are controlled by mammalian and bacterial promoters in tandem (see Figure 7 ) or only one (e.g., HC) cassette is under the control of a tandem mammalian and bacterial promoter, while the other (e.g., LC) cassette is under the control of a bacterial promoter only (see Fig.14 ).
[0104] In addition, the vector includes a bacterial origin of replication, a mammalian origin of replication, a nucleic acid encoding a protein used as a control (e.g., a gD protein), or a protein for activities such as protein purification, protein tagging, protein labeling, such as labeling with a detectable compound or composition (e.g., a radioactive label, a fluorescent label, or an enzymatic label).
[0105] In one embodiment, mammalian and bacterial promoters and signal sequences are operably linked to the antibody light chain sequence, and mammalian and bacterial promoters and signal sequences are operably linked to the antibody heavy chain sequence.
[0106] D. Selection and screening of antibodies against target antigens
[0107] The present invention provides a method for screening and selecting antibodies against a target protein by displaying a Fab-based library on phage or bacteria, or optimizing existing antibodies by a similar method. The above-mentioned dual vector can be used to screen and select Fab fragments in prokaryotic cells, and the selected Fab can be easily expressed as a full-length IgG molecule for further testing without the need for subcloning.
[0108] Antibodies of the present invention
[0109] In another aspect of the invention, the antibody according to any of the above embodiments is a monoclonal antibody, including chimeric, humanized or human antibodies. In one embodiment, the antibody is an antibody fragment, such as Fv, Fab, Fab', scFv, diabody or F(ab'). 2 Fragments. In another embodiment, the antibody is a full-length antibody, such as an intact IgG1, IgG2, IgG3 or IgG4 antibody or other antibody class or isotype as defined herein.
[0110] In further aspects, the antibody according to any of the above embodiments may comprise any of the properties described in Sections 1-7 below, alone or in combination.
[0111] 1. Antibody affinity
[0112] In certain embodiments, the antibodies provided herein have a molecular weight of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or less, e.g. 10 -8 M to 10 -13 M, for example, 10 -9 M to 10 -13 The dissociation constant (Kd) of the
[0113] In one embodiment, Kd is measured by performing a radiolabeled antigen binding assay (RIA) using a Fab version of the antibody of interest and its antigen as described by the following assay. In the presence of a titration series of unlabeled antigen, Kd is measured by using a minimum concentration ( 125 The solution binding affinity of Fab for antigen is measured by equilibrating Fab with I)-labeled antigen and then capturing bound antigen with an anti-Fab antibody-coated plate (see, e.g., Chen et al., J. Mol. Biol. 293:865-881 (1999)). To establish the conditions for the assay, Multiwell plates (ThermoScientific) were coated overnight with 5 μg / ml capture anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6) and subsequently blocked with 2% (w / v) bovine serum albumin in PBS for 2 to 5 hours at room temperature (approximately 23°C). In non-adsorbent plates (Nunc #269620), 100 pM or 26 pM [ 125 I]-antigen is mixed with serial dilutions of the Fab of interest (e.g., consistent with the evaluation of anti-VEGF antibody, Fab-12 in Presta et al., Cancer Res. 57:4593-4599 (1997)). The Fab of interest is then incubated overnight; however, the incubation can be continued for a longer period of time (e.g., about 65 hours) to ensure that equilibrium is reached. The mixture is then transferred to the capture plate and incubated at room temperature (e.g., 1 hour). The solution is then removed and washed with 0.1% polysorbate 20 in PBS. Wash the plate 8 times. When the plate is dry, add 150 μl / well of scintillant (MICROSCINT-20 TM ; Packard) and in TOPCOUNT TM Counting was performed on a gamma counter (Packard) for 10 min. Concentrations of each Fab that gave less than or equal to 20% of maximal binding were chosen for use in competition binding assays.
[0114] According to another embodiment, an immobilized antigen CM5 chip was used at ∼10 response units (RU) at 25°C. -2000 or -3000 (BIAcore, Inc., Piscataway, NJ), using surface plasmon resonance assay to measure Kd. Briefly, carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.) were activated with N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and: N-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigens were diluted to 5 μg / ml (~0.2 μM) with 10 mM sodium acetate, pH 4.8 before injection at a flow rate of 5 μl / min to achieve approximately 10 response units (RU) of coupled protein. After injection of antigen, 1 M ethanolamine was injected to block unreacted groups. For kinetic measurements, the cells were incubated at 25°C in a 4% PBS solution with 0.05% polysorbate 20 (TWEEN-20 TM Two-fold serial dilutions of Fab (0.78 nM to 500 nM) were injected in PBS containing 1% paraformaldehyde (PBST) at a flow rate of approximately 25 μl / min. A simple one-to-one Langmuir binding model ( The binding rate (k on ) and the dissociation rate (koff). The equilibrium dissociation constant (Kd) was calculated as the ratio k off / k on See, for example, Chen et al., J. Mol. Biol. 293:865-881 (1999). If the on-rate measured by the surface plasmon resonance measurement method exceeds 10 6 M -1 s -1 , the on-rate can be determined using a fluorescence quenching technique, which measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm bandpass) of 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen at 25°C, as measured in a spectrophotometer such as a Spectrophotometer equipped with a cutoff (Aviv Instruments) or an 8000-series SLM-AMINCO TM Measured in a spectrophotometer (ThermoSpectronic) using a stirred cuvette.
[0115] 2. Antibody fragments
[0116] In certain embodiments, the antibodies provided herein are antibody fragments. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab') 2 , Fv and scFv fragments, as well as the other fragments described below. For a review of certain antibody fragments, see Hudson et al. Nat. Med. 9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthün, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For Fab and F(ab') fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life 2 For a discussion of fragments, see U.S. Patent No. 5,869,046.
[0117] Diabodies are antibody fragments with two antigen binding sites that can be bivalent or bispecific. See, e.g., EP 404,097; WO 1993 / 01161; Hudson et al., Nat. Med. 9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med. 9:129-134 (2003).
[0118] Single domain antibodies are antibody fragments that contain all or a portion of the heavy chain variable region or all or a portion of the light chain variable region of an antibody. In certain embodiments, the single domain antibody is a human single domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Pat. No. 6,248,516 Bl).
[0119] As described herein, antibody fragments can be prepared by a variety of techniques, including, but not limited to, hydrolytic digestion of intact antibodies, and production by recombinant host cells (eg, E. coli or phage).
[0120] 3. Chimeric and humanized antibodies
[0121] In certain embodiments, the antibodies provided herein are chimeric antibodies. Certain chimeric antibodies are described in, for example, U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81: 6851-6855 (1984). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate such as a monkey) and a human constant region. In another example, a chimeric antibody is a "class switched" antibody, in which the class or subclass is changed from the class or subclass of the parent antibody. Chimeric antibodies include antigen binding fragments thereof.
[0122] In certain embodiments, chimeric antibodies are humanized antibodies. Typically, humanized non-human antibodies are used to reduce immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. Typically, humanized antibodies include one or more variable regions, wherein HVR, such as CDR (or portions thereof) are derived from non-human antibodies, and FR (or portions thereof) are derived from human antibody sequences. Humanized antibodies optionally also include at least a portion of human constant regions. In some embodiments, some FR residues in humanized antibodies are replaced with corresponding residues from non-human antibodies (e.g., antibodies derived from HVR residues), to restore or improve antibody specificity or affinity.
[0123] Humanized antibodies and methods for making them are reviewed in, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described in, e.g., Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Nat'l Acad. Sci. USA 86:10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describing SDR(a-CDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describing “resurfacing”); Dall'Acqua et al., Methods 36:43-60 (2005) (describing “FR shuffling”); and Osbourn et al., Methods 36:61-68 (2005) and Klimka et al., Br. J. Cancer, 83:252-260 (2000) (describing the “guided selection” method of FR shuffling).
[0124] Human framework regions that can be used for humanization include, but are not limited to, framework regions selected using the "best-fit" method (see, e.g., Sims et al. J. Immunol. 151:2296 (1993)); framework regions derived from the consensus sequence of the light chain or heavy chain variable regions of a particular subgroup of human antibodies (see, e.g., Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol., 151:2623). (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008)); and framework regions derived from screening FR libraries (see, e.g., Baca et al., J. Biol. Chem. 272:10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271:22611-22618 (1996))
[0125] 4. Human Antibodies
[0126] In certain embodiments, the antibodies provided herein are human antibodies. Human antibodies can be produced using a variety of techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5: 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20: 450-459 (2008).
[0127] Human antibodies can be prepared by administering an immunogen to a transgenic animal that is modified to produce complete human antibodies or complete antibodies with human variable regions in response to an antigen attack. Such animals typically contain all or part of a human immunoglobulin locus, all or part of which replaces the endogenous immunoglobulin locus, or all or part of which exists extrachromosomally or is randomly integrated into the chromosome of the animal. In such transgenic mice, the endogenous immunoglobulin locus is typically inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, Nat. Biotech. 23: 1117-1125 (2005). See also, for example, description of XENOMOUSE TM U.S. Patent Nos. 6,075,181 and 6,150,584 for the technology; description US Patent No. 5,770,429 for technology; description U.S. Patent No. 7,041,870, and description of Human variable regions from intact antibodies produced by such animals can be further modified, for example, by combining with different human constant regions.
[0128] Human antibodies can also be prepared by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g., Kozbor J. Immunol., 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al., J. Immunol., 147: 86 (1991)). Human antibodies produced by human B-cell hybridoma technology are also described in Li et al., Proc. Natl. Acad. Sci. USA, 103: 3557-3562 (2006). Other methods include those described, for example, in U.S. Pat. No. 7,189,826 (describing the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers and Brandlein, Histology and Histopathology, 20(3):927-937 (2005) and Vollmers and Brandlein, Methods and Findings in Experimental and Clinical Pharmacology, 27(3):185-91 (2005).
[0129] It is also possible to produce human antibodies by cloning variable region sequences of the Fv separation selected from a phage display library derived from humans. Then, such variable region sequences can be combined with desired human constant regions. The technology for selecting human antibodies from antibody libraries is described below.
[0130] 5. Antibodies derived from the library
[0131] Antibodies of the invention can be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, various methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed in, for example, Hoogenboom et al. in Methods in Molecular Biology 178: 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001), and further described in, for example, McCafferty et al., Nature 348: 552-554; Clackson et al., Nature 352: 624-628 (1991); Marks et al., J. Mol. Biol. 222: 581-597 (1992); Marks and Bradbury, in Methods in Molecular Biology 248: 161-175 (Lo, ed., Human Press, Totowa, NJ, 2003); Sidhu et al., J. Mol. Biol. 338(2):299-310 (2004); Lee et al., J. Mol. Biol. 340(5):1073-1093 (2004); Fellouse, Proc. Natl. Acad. Sci. USA 101(34):12467-12472 (2004); and Lee et al., J. Immunol. Methods 284(1-2):119-132 (2004).
[0132] In some phage display methods, as described in Winter et al., Ann. Rev. Immunol., 12: 433-455 (1994), the full repertoire of VH and VL genes is cloned by polymerase chain reaction (PCR), respectively, and randomly combined in a phage library, which can then be screened for antigen binding phage. Phages typically display antibody fragments, single-chain Fv (scFv) fragments or Fab fragments. In the absence of the need to construct hybridomas, libraries from immune sources provide high-affinity antibodies to immunogens. Alternatively, as described by Griffiths et al., EMBO J, 12: 725-734 (1993), natural full repertoires (e.g., from humans) can be cloned to provide a wide range of non-self and autoantibodies to antibodies from a single source without any immunization. Finally, as described by Hoogenboom and Winter, J.Mol.Biol., 227:381-388 (1992), natural libraries can also be prepared synthetically by cloning unrearranged V-gene segments from stem cells and using PCR primers containing random sequences to encode highly variable CDR3 regions and complete in vitro rearrangement. Patent documents describing human antibody phage libraries include, for example: U.S. Patent No. 5,750,373 and U.S. Patent Publication Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936 and 2009 / 0002360.
[0133] Herein, antibodies or antibody fragments isolated from a human antibody library are considered human antibodies or human antibody fragments.
[0134] 6. Multispecific Antibodies
[0135] In certain embodiments, the antibodies provided herein are multispecific antibodies, such as bispecific antibodies. Multispecific antibodies are monoclonal antibodies that have binding specificity to at least two different sites. In certain embodiments, one binding specificity is for a first antigen, and the other binding specificities are for any other antigen. In certain embodiments, bispecific antibodies can bind to two different epitopes of the first antigen. Bispecific antibodies can also be used to localize cytotoxic agents to cells expressing the first antigen. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.
[0136] Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature, 305:537 (1983), WO 93 / 08829, and Traunecker et al., EMBO J. 10:3655 (1991)), and “knob-in-hole” engineering (see, e.g., U.S. Pat. No. 5,731,168). It is also possible to engineer the electrostatic steering effect for preparing antibody Fc-heterodimer molecules (WO2009 / 089004A1); cross-link two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980 and Brennan et al., Science, 229:81 (1985)); use leucine zippers to produce bispecific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); use for preparing bispecific antibodies. Multispecific antibodies can be prepared by the "diabody" technology of using specific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain Fv (sFv) dimers (see, e.g., Gruber et al., J. Immunol., 152:5368 (1994)); and preparing trispecific antibodies as described, e.g., in Tutt et al., J. Immunol. 147:60 (1991).
[0137] Also included herein are engineered antibodies having three or more functional antigen binding sites, including "Octopus antibodies", see, e.g., US 2006 / 0025576 A1.
[0138] As used herein, antibodies or fragments also include "Dual Acting FAb" or "DAF", which comprise an antigen binding site that binds to a first antigen as well as another, different antigen (see, e.g., US 2008 / 0069820).
[0139] 7. Antibody variants
[0140] In certain embodiments, it is contemplated that amino acid sequence variants of antibodies are provided herein. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the antibody may be prepared by introducing suitable modifications into the nucleotide sequence encoding the antibody or by peptide synthesis. Such modifications include, for example, deletions and / or insertions and / or replacement residues in the amino acid sequence of the antibody. Any combination of deletions, insertions and replacements may be performed to obtain the final construct, as long as the final construct possesses desired features such as antigen binding.
[0141] a) Substitution, insertion and deletion variants
[0142] In certain embodiments, antibody variants with one or more amino acid substitutions are provided. The target sites for substitution mutagenesis include HVR and FR. In Table 1, conservative substitutions are shown under the heading "conservative substitutions". In Table 1, more substitution changes are provided under the heading "exemplary substitutions", and are further described below with reference to the amino acid side chain species. Amino acid substitutions can be introduced into the target antibody, and the product can be screened for desired activity, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.
[0143] Table 1
[0144]
[0145] Amino acids can be grouped according to common side chain properties:
[0146] (1) Hydrophobicity: norleucine, Met, Ala, Val, Leu, Ile;
[0147] (2) Neutral hydrophilicity: Cys, Ser, Thr, Asn, Gln;
[0148] (3) Acidic: Asp, Glu;
[0149] (4) Basic: His, Lys, Arg;
[0150] (5) Residues that affect chain direction: Gly, Pro;
[0151] (6) Aromatic: Trp, Tyr, Phe.
[0152] Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
[0153] One type of substitution variant involves replacing one or more hypervariable region residues of a parent antibody (e.g., a humanized or human antibody). Typically, the variants selected for further study have modifications (e.g., improvements) in certain biological properties relative to the parent antibody (e.g., increased affinity, reduced immunogenicity) and / or certain biological properties of the parent antibody that are substantially retained. Exemplary substitution variants are affinity-matured antibodies, which can be routinely produced, for example, using affinity maturation techniques based on phage display as described herein. In short, one or more HVR residues are mutated, and the variant antibodies are displayed on phage and screened for specific biological activities (e.g., binding affinity).
[0154] Changes (e.g., substitutions) can be made in HVR to improve antibody affinity. Such changes can be made in HVR "hotspots" (i.e., residues encoded by codons that undergo high-frequency mutations during the somatic maturation process) (see, e.g., Chowdhury, Methods Mol. Biol. 207: 179-196 (2008)) and / or SDR (a-CDR), and the resulting variant VH or VL binding affinity is tested. For example, Hoogenboom et al. have described affinity maturation by building and reselecting from a second library in Methods in Molecular Biology 178: 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, (2001)). In some embodiments of affinity maturation, diversity is introduced into the variable genes selected for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-guided mutagenesis). A second library is then generated. The library is then screened to identify any antibody variant with the desired affinity. Another method of introducing diversity involves an HVR-guided approach in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues that are involved in antigen binding can be specifically identified, for example, using alanine scanning mutagenesis or modeling. In particular, CDR-H3 and CDR-L3 are typically targeted.
[0155] In certain embodiments, substitutions, insertions or deletions may occur in one or more HVRs, as long as such changes do not substantially reduce the ability of the antibody to bind to antigen. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such changes may be outside HVR "hot spots" or SDRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR has no changes or contains no more than 1, 2 or 3 amino acid substitutions.
[0156] As described by Cunningham and Wells (1989) Science, 244: 1081-1085, a useful method for identifying residues or regions of antibodies that can be targets for mutagenesis is called "alanine scanning mutagenesis". In this method, residues or target residue groups (e.g., charged residues such as arg, asp, his, lys and glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen will be affected. Additional replacements can be introduced at amino acid positions that initially exhibit functional sensitivity to the replacement. Alternatively or additionally, the crystal structure of the antigen-antibody complex can be used to identify contact points between the antibody and the antigen. Such contact residues and adjacent residues can be targeted and removed as candidates for replacement. Variants can be screened to determine whether they contain desired properties.
[0157] Amino acid sequence insertions include amino-terminal and / or carboxyl-terminal fusions of one residue to polypeptide lengths of hundreds or more residues, and intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include antibodies with an amino-terminal methionyl residue. Other insertion variants of antibody molecules include fusions of the amino-terminal or carboxyl-terminal ends of antibodies with enzymes (e.g., ADEPT) or polypeptides that can increase the serum half-life of antibodies.
[0158] b) Glycosylation variants
[0159] In certain embodiments, the antibodies provided herein are altered to increase or decrease the degree of antibody glycosylation. The addition or deletion of antibody glycosylation sites can be routinely achieved by changing the amino acid sequence to create or remove one or more glycosylation sites.
[0160] When antibody comprises Fc district, the sugar that it is connected can be changed.Natural antibodies produced by mammalian cells usually comprise branched, bibranched oligosaccharides, which are usually connected to the Asn297 of the CH2 domain in the Fc district by N-connection.See, for example, Wright et al. TIBTECH 15:26-32 (1997).Oligosaccharides can include a variety of sugars, such as mannose, N-acetylglucosamine (GlcNAc), galactose and sialic acid, and the fucose connected with GlcNAc in the "stem" of bibranched oligosaccharide structure.In some embodiments, oligosaccharide modification can be carried out in antibodies of the present invention to produce antibody variants with some improved properties.
[0161] In one embodiment, the antibody variants provided have a sugar structure lacking fucose connected (directly or indirectly) to the Fc region. For example, the amount of fucose in the antibody can be 1% to 80%, 1% to 65%, 5% to 65% or 20% to 40%. As described in WO 2008 / 077546, for example, the amount of fucose can be determined by calculating the average amount of fucose in the sugar chain at Asn297 relative to the sum of all sugar structures (e.g., complexes, hybrids, and high mannose structures) connected to Asn 297 measured by MALDI-TOF mass spectrometry. Asn297 refers to an asparagine residue located at approximately position 297 in the Fc region (Eu numbering of Fc region residues); however, due to less sequence variation in antibodies, Asn297 can also be located about ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300. Such fucosylated variants can improve ADCC function. See, for example, US Patent Publication Nos. US 2003 / 0157108 (Presta, L.); US 2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of literature related to "defucosylated" or "fucose-deficient" antibody variants include: US2003 / 0157108; WO 2000 / 61739; WO 2001 / 29246; US2003 / 0115614; US2002 / 0164328; US2004 / 0093621; US2004 / 0132140; US2004 / 0110704; US 2004 / 0110282; US2004 / 0109865; WO 2003 / 085119; WO 2003 / 084570; WO 2005 / 035586; WO 2005 / 035778; WO2005 / 053742; WO2002 / 031140; Okazaki et al. J. Mol. Biol. 336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng. 87:614 (2004).Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells lacking protein fucosylation (Ripka et al. Arch. Biochem. Biophys. 249: 533-545 (1986); US Patent Application No. US2003 / 0157108A1, Presta, L; and WO 2004 / 056312 A1, Adams et al., particularly in Example 11), and knockout cell lines, such as CHO cells in which the α-1,6-fucosyltransferase gene, FUT8, is knocked out (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng. 87: 614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94(4): 680-688 (2006); and WO2003 / 085107).
[0162] Also provided are antibody variants with bisected oligosaccharides, such as bi-branched oligosaccharides connected to the Fc region of the antibody by GlcNAc bisection. Such antibody variants may have reduced fucosylation and / or improved ADCC function. Examples of such antibody variants are described in, for example, WO 2003 / 011878 (Jean-Mairet et al.); U.S. Patent No. 6,602,684 (Umana et al.); and US2005 / 0123546 (Umana et al.). Also provided are antibody variants having at least one galactose residue in the oligosaccharide connected to the Fc region. Such antibody variants have improved CDC function. Such antibody variants are described in, for example, WO 1997 / 30087 (Patel et al.); WO 1998 / 58964 (Raju, S.); and WO 1999 / 22764 (Raju, S.).
[0163] c) Fc region variants
[0164] In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. An Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region) comprising an amino acid modification (e.g., replacement) at one or more amino acid positions.
[0165] In certain embodiments, the present invention contemplates antibody variants that possess some but not all effector functions, which render the antibody variant a desirable candidate for applications in which the in vivo half-life of the antibody is important, while certain effector functions (e.g., complement and ADCC) are unnecessary or disadvantageous. In vitro and / or in vivo cytotoxicity assays may be performed to confirm the reduction / absence of CDC and / or ADCC activity. For example, an Fc receptor (FcR) binding assay may be performed to ensure that the antibody lacks FcγR binding (and therefore may lack ADCC activity), but retains FcRn binding ability. NK cells, the main cells that regulate ADCC, express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9: 457-492 (1991). Non-limiting examples of in vitro assays for evaluating ADCC activity of a molecule of interest are described in U.S. Pat. Nos. 5,500,362 (see, e.g., Hellstrom, I. et al. Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); 5,821,337 (see Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assays can be used (see, e.g., ACTI for flow cytometry (Cell Technology, Inc. Mountain View, CA)). TM Non-radioactive cytotoxicity assays; and CytoTox Non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, ADCC activity of the molecule of interest can be assessed in vivo in an animal model such as disclosed in Clynes et al. Proc. Nat'l Acad. Sci. USA 95:652-656 (1998). A C1q binding assay can also be performed to confirm that the antibody cannot bind to C1q and therefore lacks CDC activity. See, e.g., C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activity, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996); Cragg, MS et al., Blood 101: 1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103: 2738-2743 (2004)). FcRn binding and in vivo clearance / half-life assays can also be performed using methods known in the art (see, e.g., Petkova, SB et al., Int'l. Immunol. 18 (12): 1759-1769 (2006)).
[0166] Antibodies with reduced effector function include those with one or more Fc region residues 238, 265, 269, 270, 297, 327 and 329 substituted antibodies (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more amino acid positions 265, 269, 270, 297 and 327, including an Fc mutant called "DANA" with residues 265 and 297 substituted with alanine (U.S. Pat. No. 7,332,581).
[0167] Certain antibody variants with improved or reduced binding to FcRs are described (see, e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312, and Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001)).
[0168] In certain embodiments, the antibody variants comprise an Fc region with one or more amino acid substitutions that improve ADCC, such as substitutions at positions 298, 333, and / or 334 of the Fc region (EU numbering of residues).
[0169] In some embodiments, alterations are made in the Fc region that result in altered (ie, improved or reduced) CIq binding and / or complement dependent cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99 / 51642, and Idusogie et al. J. Immunol. 164:4178-4184 (2000).
[0170] Antibodies with increased half-life and improved binding to the neonatal Fc receptor (FcRn) are described in US 2005 / 0014934A1 (Hinton et al.), which is responsible for the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)). These antibodies comprise an Fc region with one or more substitutions therein that improves the binding of the Fc region to FcRn. Such Fc variants include those having substitutions at one or more Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, for example, an Fc variant having substitutions at Fc region residue 434 (U.S. Pat. No. 7,371,826).
[0171] See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Pat. No. 5,648,260; U.S. Pat. No. 5,624,821; and WO 94 / 29351 for other examples of Fc region variants.
[0172] d) Cysteine engineered antibody variants
[0173] In certain embodiments, it is desirable to produce cysteine engineered antibodies, such as "thioMAbs," in which one or more residues of an antibody are replaced with cysteine residues. In a specific embodiment, the replaced residues are present at accessible sites of the antibody. As further described herein, by replacing these residues with cysteine, active thiol groups are placed at accessible sites of the antibody, and can be used for conjugation of antibodies with other moieties, such as drug moieties or linker-drug moieties, to produce immunoconjugates. In certain embodiments, one or more of the following residues can be replaced with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) in the heavy chain Fc region. Cysteine engineered antibodies can be produced, for example, as described in U.S. Patent No. 7,521,541.
[0174] e) Antibody derivatives
[0175] In certain embodiments, the antibodies provided herein can be further modified to contain other non-proteinaceous moieties known in the art and readily available. Suitable moieties for derivatizing antibodies include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol / propylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-triazine ... Polyethylene glycol propionaldehyde has advantages in production due to its stability in water. The polymer can have any molecular weight and can be branched or unbranched. The number of polymers attached to the antibody can be varied, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the specific properties or functions of the antibody to be improved, whether the antibody derivative is used for treatment under defined conditions, etc.
[0176] In another embodiment, a polymer of an antibody and a non-protein portion that can be selectively heated by exposure to radiation is provided. In one embodiment, the non-protein portion is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation can be of any wavelength, and includes but is not limited to wavelengths that will not harm ordinary cells, but which can heat the non-protein portion to a temperature that can kill cells adjacent to the antibody-non-protein portion.
[0177] Recombinant methods and compositions
[0178] Antibodies can be produced using, for example, recombinant methods and compositions as described in U.S. Patent No. 4,816,567. In one embodiment, an isolated nucleic acid encoding an antibody as described herein is provided. Such nucleic acid can encode an amino acid sequence comprising the VL of an antibody and / or an amino acid sequence comprising the VH (e.g., a light chain and / or a heavy chain of an antibody). In another embodiment, one or more vectors (e.g., an expression vector) comprising the nucleic acid are provided. In another embodiment, a host cell comprising the nucleic acid is provided. In one such embodiment, the host cell comprises (e.g., has been transformed): (1) a vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of an antibody and an amino acid sequence comprising the VH of an antibody, or (2) a first vector comprising a nucleic acid encoding an amino acid sequence comprising the VL of an antibody and a second vector comprising a nucleic acid encoding an amino acid sequence of the VH of an antibody. In one embodiment, the host cell is a eukaryotic cell, such as a Chinese hamster ovary (CHO) cell or a lymphoid cell (e.g., a Y0, NS0, Sp20 cell). In one embodiment, a method for preparing an antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody as provided above under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
[0179] For the recombinant production of antibodies, nucleic acids encoding antibodies, such as described above, are isolated and inserted into one or more vectors for further cloning and / or expression in host cells. The nucleic acids can be easily isolated and sequenced using conventional methods (e.g., by using oligonucleotide probes that specifically bind to the genes encoding the heavy and light chains of the antibodies).
[0180] Suitable host cells for cloning and expressing vectors encoding antibodies include prokaryotic or eukaryotic cells described herein. For example, particularly when glycosylation and Fc effector functions are not required, antibodies can be produced in bacteria. For expressing antibody fragments and polypeptides in bacteria, see, for example, U.S. Patent Nos. 5,648,237, 5,789,199 and 5,840,523 (also see Charlton, Methods in Molecular Biology, Vol. 248 (BKCLo ed., Humana Press, Totowa, NJ, 2003), pp. 245-254), describing expression of antibody fragments in Escherichia coli). After expression, antibodies can be separated from the bacterial cell paste in the soluble component and can be further purified.
[0181] In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized," resulting in the production of antibodies with partially or fully human glycosylation patterns. See Gerngross, Nat. Biotech. 22: 1409-1414 (2004) and Li et al., Nat. Biotech. 24: 210-215 (2006).
[0182] Suitable host cells for expressing glycosylated antibodies can also be derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrates include plant and insect cells. Numerous baculovirus strains have been identified that can be used for conjugation with insect cells, particularly for transfecting Spodoptera frugiperda cells.
[0183] Plant cell cultures can also be used as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES for producing antibodies in transgenic plants). TM technology).
[0184] Vertebrate cells can also be used as hosts. For example, mammalian cells suitable for culture in suspension can be used. Other examples of useful mammalian host cell lines are monkey kidney CV1 cell line (COS-7) transformed by SV40; human embryonic kidney cell line (e.g., 293 or 293 cells as described in Graham et al., J. Gen Virol. 36:59 (1977)); hamster baby kidney cells (BHK); mouse Sertoli cells (e.g., TM4 cells as described in Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical cancer cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A)); human lung cells (W138); human liver cells (HepG2); mouse mammary tumor (MMT 060562); TRI cells, e.g., as described in Mather et al., Annals N.Y. Acad. Sci. 383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR -CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo ed., Humana Press, Totowa, NJ), pp. 255-268 (2003).
[0185] Determination method
[0186] The antibodies provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activities by a variety of assays known in the art.
[0187] 1. Binding and other assays
[0188] In one aspect, the antigen binding activity of the antibodies of the invention is tested, for example, by known methods such as ELISA, Western blot, and the like.
[0189] On the other hand, competition assays can be used to identify antibodies that compete with the antibodies of the present invention for binding to the antigen of interest. In certain embodiments, the competing antibodies bind to the same epitope (e.g., linear or conformational epitope) that the antibodies of the present invention bind to. In Morris (1996) "Epitope Mapping Protocols", detailed exemplary methods for mapping epitopes that bind to antibodies are provided in Methods in Molecular Biology vol. 66 (Humana Press, Totowa, NJ).
[0190] In an exemplary competitive assay, an immobilized target antigen is incubated in a solution comprising a first labeled antibody (e.g., an antibody of the present invention) that is bound to the target antigen and a second unlabeled antibody to be tested for its ability to compete with the first antibody for binding to the target antigen. The second antibody may be present in a hybridoma supernatant. As a control, the immobilized target antigen is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions that allow the first antibody to bind to the target antigen, excess unbound antibody is removed, and the amount of labeling associated with the immobilized target antigen is measured. If the amount of labeling bound to the immobilized target antigen is significantly reduced in the test sample relative to the control sample, it means that the second antibody competes with the first antibody for binding to the target antigen. See Harlow and Lane (1988) Antibodies: A Laboratory Manual ch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).
[0191] 2. Activity Assay
[0192] In one aspect, assays are provided for identifying antibodies having biological activity. Antibodies having the biological activity in vivo and / or in vitro are also provided.
[0193] In certain embodiments, antibodies of the invention are tested for this biological activity.
[0194] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the present invention in any way.
[0195] All patent and literature references cited in this specification are hereby incorporated by reference in their entirety.
[0196] Specific embodiments of the present invention
[0197] 1. A nucleic acid molecule encoding a first polypeptide comprising VH-HVR1, VH-HVR2 and VH-HVR3 of a variable heavy chain domain (VH) and / or a second polypeptide comprising VL-HVR1, VL-HVR2 and VL-HVR3 of a variable light chain domain (VL), and wherein the nucleic acid molecule further encodes a signal sequence that functions in both prokaryotes and eukaryotic cells, and the signal sequence is encoded by a nucleic acid sequence operably linked to the first and / or second polypeptide sequence, and wherein a full-length antibody is expressed from the first and / or second polypeptide of the nucleic acid molecule.
[0198] 2. A nucleic acid molecule encoding a variable heavy chain (VH) domain and a variable light chain (VL) domain, and comprising a prokaryotic promoter and / or a eukaryotic promoter, the promoter being operably linked to the VH domain and / or VL domain to allow expression of the VH domain and / or VL domain in prokaryotic and eukaryotic cells, and wherein when expressed by eukaryotic cells, the VH domain and / or VL is linked to a utility peptide, and wherein the nucleic acid also encodes a signal sequence that functions in both prokaryotic and eukaryotic cells.
[0199] 3. The nucleic acid molecule of embodiment 1, wherein the VL and VH are linked to a utility peptide.
[0200] 4. The nucleic acid molecule of embodiment 3, wherein the VH is further connected to CH1, and the VL domain is connected to CL.
[0201] 5. The nucleic acid molecule of embodiment 4, wherein the utility peptide is selected from the group consisting of Fc, a tag, a marker, and a control protein.
[0202] 6. The nucleic acid molecule of embodiment 5, wherein the VL is linked to a control protein and the VH is linked to Fc.
[0203] 7. The nucleic acid molecule of embodiment 6, wherein the control protein is gD protein or a fragment thereof.
[0204] 8. The nucleic acid molecule of embodiment 1, wherein the first and / or second polypeptide is fused to a coat protein or a linker protein.
[0205] 9. The nucleic acid molecule of embodiment 8, wherein the nucleic acid encoding the coat protein or the linker protein is contained in a synthetic intron.
[0206] 10. The nucleic acid molecule of embodiment 9, wherein the synthetic intron is located between the nucleic acid encoding the VH domain and the nucleic acid encoding the Fc or hinge.
[0207] 11. The nucleic acid molecule of embodiment 10, wherein the synthetic intron further comprises a nucleic acid encoding a naturally occurring intron from IgG1.
[0208] 12. The nucleic acid molecule of embodiment 11, wherein the naturally occurring intron is selected from intron 1, intron 2 or intron 3 from IgG1.
[0209] 13. The nucleic acid molecule of embodiment 12, wherein the naturally occurring intron is intron 1 from IgG1.
[0210] 14. The nucleic acid molecule of embodiment 8, wherein the linker protein is a leucine zipper.
[0211] 15. The nucleic acid molecule of embodiment 8, wherein the linker protein comprises the amino acid sequence of SEQ ID NO: 8, 9, 12, 13, 14 or 15.
[0212] 16. The nucleic acid molecule of embodiment 8, wherein the connector protein comprises an amino acid sequence having at least one amino acid modification of SEQ ID NO: 8, 9, 12, 13, 14 or 15, and wherein the connector protein comprises a modification of at least one residue of the amino acid sequence of SEQ ID NO: 8, 9, 12, 13, 14 or 15, and wherein the modification retains or increases the affinity of the connector protein for another connector protein.
[0213] 17. The nucleic acid molecule of embodiment 8, wherein the coat protein is selected from pi, pII, pill, pIV, pV, pVI, pVII, pVIII, pIX and pX of bacteriophage M13, fl or fd.
[0214] 18. The nucleic acid molecule of embodiment 17, wherein the coat protein is pill protein or a fragment thereof.
[0215] 19. The nucleic acid molecule of embodiment 18, wherein the pill fragment is amino acids 267-421 or 262-418 of the pill protein.
[0216] 20. The nucleic acid molecule of embodiment 17, wherein in prokaryotic cells, the first fusion protein is expressed, and in eukaryotic cells, the second fusion protein is expressed.
[0217] 21. The nucleic acid molecule of embodiment 20, wherein the first fusion protein and the second fusion protein are the same.
[0218] 22. The nucleic acid molecule of embodiment 20, wherein the first fusion protein and the second fusion protein are different.
[0219] 23. The nucleic acid molecule of embodiment 22, wherein the first fusion protein is a Fab-phage fusion protein.
[0220] 24. The nucleic acid molecule of embodiment 23, wherein the Fab-phage fusion protein comprises VH / CH1 fused to pill.
[0221] 25. The nucleic acid molecule of embodiment 24, wherein the second fusion is a Fab-Fc or Fab-hinge-Fc fusion protein.
[0222] 26. The nucleic acid molecule of embodiment 25, wherein the Fab-Fc or Fab-hinge-Fc fusion protein comprises VH / CH1 fused to Fc.
[0223] 27. The nucleic acid molecule of embodiment 1, wherein the signal sequence directs protein secretion to the endoplasmic reticulum or outside the cell in eukaryotic cells.
[0224] 28. The nucleic acid molecule of embodiment 1, wherein the signal sequence directs protein secretion to the periplasm or outside the cell in prokaryotic cells.
[0225] 29. The nucleic acid molecule of embodiment 28, wherein the nucleic acid encoding the CH1 domain comprises a portion of a native splice donor sequence.
[0226] 30. The nucleic acid molecule of embodiment 28, wherein said nucleic acid encoding said Fc comprises a portion of a natural splice acceptor sequence.
[0227] 31. The nucleic acid molecule of embodiment 28, wherein the nucleic acid encoding the CH1 domain comprises a portion of a modified splice donor sequence.
[0228] 32. The nucleic acid molecule of embodiment 31, wherein the modified splice donor sequence comprises a modification of at least one nucleic acid residue, and wherein the modification increases splicing.
[0229] 33. The nucleic acid molecule of embodiment 8, wherein the linker protein comprises an amino acid sequence selected from SEQ ID NO: 6 (ASIARLRERVKTLRARNYELRSRANMLRERVAQLGGC) or SEQ ID NO: 7 (ASLDELEAEIEQLEEENYALEKEIEDLEKELEKLGGC).
[0230] 34. The nucleic acid molecule of embodiment 2, wherein the prokaryotic promoter is phoA, Tac, Tphac or La c Promoter.
[0231] 35. The nucleic acid molecule of embodiment 2, wherein the eukaryotic promoter is CMV or SV40.
[0232] 36. The nucleic acid molecule of embodiment 27 or 28, wherein the signal sequence is encoded by a nucleic acid encoding an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 10 (XMKFTVVAAALLLLGAVRA), wherein X=0 amino acids or 1 or 2 amino acids (e.g., X=M or X=MT or X is missing).
[0233] 37. The nucleic acid molecule of embodiment 27 or 28, wherein the signal sequence is encoded by a nucleic acid sequence encoding mBIP or a variant thereof.
[0234] 38. The nucleic acid molecule of embodiments 27-28, wherein the signal sequence is encoded by a nucleic acid sequence encoding an amino acid sequence having at least 85% amino acid sequence identity with an amino acid sequence selected from SEQ ID NO: 3 (mBIP amino acid sequence), and wherein the signal sequence functions in both prokaryotic and eukaryotic cells.
[0235] 39. The nucleic acid molecule of embodiments 27-28, wherein the signal sequence is encoded by the nucleic acid sequence of SEQ ID NO: 11 (consensus mBIP sequence, X ATG AAN TTN ACN GTN GTN GCN GCN GCNCTN CTN CTN CTN GGN GCN GTN CGN GCN, wherein N=A, T, C or G, wherein X=ATG, X=ATG ACC or X=deletion).
[0236] 40. The nucleic acid molecule of embodiment 27, wherein the signal sequence is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 16 (Opt1), SEQ ID NO: 17 (Opt2) and SEQ ID NO: 18 (Opt3).
[0237] 41. The nucleic acid molecule of embodiment 2, wherein expression via a prokaryotic promoter occurs in a bacterial cell.
[0238] 42. The nucleic acid molecule of embodiment 2, wherein expression occurs via a eukaryotic promoter in mammalian cells.
[0239] 43. The nucleic acid molecule of embodiment 41, wherein the bacterial cell is an Escherichia coli cell.
[0240] 44. The nucleic acid molecule of embodiment 42, wherein the mammalian cell is a yeast cell, a CHO cell, a 293 cell or a NSO cell.
[0241] 45. A vector comprising the nucleic acid molecule of any one of embodiments 1-44.
[0242] 46. A host cell transformed with the vector of embodiment 45.
[0243] 47. The host cell of embodiment 46, wherein the host cell is a bacterial cell.
[0244] 48. The host cell of embodiment 47, wherein the bacterial cell is an Escherichia coli cell.
[0245] 49. The host cell of embodiment 46, wherein the host cell is a eukaryotic cell.
[0246] 50. The host cell of embodiment 49, wherein the eukaryotic cell is a yeast cell, a CHO cell, a 293 cell or a NSO cell.
[0247] 51. A method for producing an antibody, comprising culturing the host cell of embodiment 46 to allow expression of the nucleic acid.
[0248] 52. The method of embodiment 51 further comprises recovering the antibody expressed by the host cell.
[0249] 53. The method of embodiment 52, wherein the antibody is recovered from the host cell culture medium.
[0250] 54. An adaptor protein comprising a modification of at least one residue of the amino acid sequence of SEQ ID NO: 8, 9, 12, 13, 14 or 15.
[0251] 55. The linker protein of embodiment 54, wherein the linker protein comprises an amino acid sequence selected from SEQ ID NO: 6 (ASIARLRERVKTLRARNYELRSRANMLRERVAQLGGC) or SEQ ID NO: 7 (ASLDELEAEIEQLEEENYALEKEIEDLEKELEKLGGC).
[0252] 56. A nucleic acid molecule encoding the adaptor protein of embodiment 54 or 55.
[0253] 57. An isolated nucleic acid molecule encoding an mBIP polypeptide that functions in both prokaryotic and eukaryotic cells, the mBIP polypeptide comprising the amino acid sequence of SEQ ID NO: 3.
[0254] 58. An isolated nucleic acid molecule encoding a polypeptide having an amino acid sequence having at least 85% amino acid sequence identity to an amino acid sequence selected from SEQ ID NO:3.
[0255] 59. A bacterial cell expressing an mBIP polypeptide or a variant thereof, wherein the mBIP polypeptide comprises the amino acid sequence of SEQ ID NO: 3.
[0256] 60. A method of expressing an mBIP polypeptide or a variant thereof in both prokaryotic and eukaryotic cells, said mBIP polypeptide comprising the amino acid sequence of SEQ ID NO: 3.
[0257] 61. The nucleic acid molecule of embodiment 9, wherein the synthetic intron is located between the nucleic acids encoding the CH2 and CH3 domains of the antibody.
[0258] 62. The nucleic acid molecule of embodiment 9, wherein the synthetic intron is located between the nucleic acids encoding the hinge region and the CH2 domain of the antibody.
[0259] 63. A polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, a variable heavy chain domain (VH) and a variable light chain domain (VL), wherein the VH domain is connected to the amino terminus of the VL domain.
[0260] 64. A polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, a variable heavy chain domain (VH) and a variable light chain domain (VL), wherein the VH domain is connected to the carboxyl terminus of the VL domain.
[0261] 65. A polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, and VH-HVR1, VH-HVR2 and VH-HVR3 of a variable heavy chain domain (VH).
[0262] 66. A polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, and VL-HVR1, VL-HVR2 and VL-HVR3 of a variable light chain domain (VL).
[0263] 67. A polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, VH-HVR1, VH-HVR2 and VH-HVR3 of a variable heavy chain domain (VH), and VL-HVR1, VL-HVR2 and VL-HVR3 of a variable light chain domain (VL).
[0264] 68. The polypeptide of embodiments 63-67, wherein the polypeptide is an antibody or an antibody fragment.
[0265] 69. The antibody or antibody fragment of embodiment 1 or 68, wherein the antibody is selected from the group consisting of F(ab')2 and Fv fragments, diabodies and single-chain antibody molecules.
[0266] 70. A nucleotide sequence of a helper phage comprising an amber mutation in pill, wherein the helper phage comprising the amber mutation enhances display of a protein fused to pill on the phage.
[0267] 71. The nucleotide sequence of embodiment 70, wherein the amber mutation is a mutation in nucleotides 2613, 2614 and 2616 of the nucleic acid of M13KO7.
[0268] 72. The nucleotide sequence of embodiment 71, wherein the mutations in nucleotides 2613, 2614 and 2616 of the nucleic acid of M13KO7 introduce an amber stop codon. III. Embodiment
[0269] The following are examples of methods and compositions of the present invention.It is understood that various other embodiments may be practiced, given the general description provided above.
[0270] M13KO7 helper phage was from New England Biolabs. Bovine serum albumin (BSA) and Tween 20 were from Sigma. Casein was from Pierce. Anti-M13 conjugated to horseradish peroxidase (HRP) was from Amersham Pharmacia. Maxisorp immunoplates were from NUNC. Tetramethylbenzidine (TMB) substrate was from Kirkegaard and Perry Laboratories. All other protein antigens were generated by the research group of Genentech, Inc.
[0271] Example 1: Selection of signal sequences for expression in prokaryotic and eukaryotic cells
[0272] To demonstrate whether the vector can express the protein of interest in both E. coli and eukaryotic (mammalian) cells, four signal sequences of non-bacterial origin were selected for which there is no controlled evidence to support the view that they can function in mammalian cells. We tested the ability of these signal sequences to drive display of anti-Her2 (h4D5) Fab on M13 phage using phage ELISA ( Figure 1A ). The levels of display were evaluated relative to the bacterial heat stable enterotoxin II (STII) signal sequence. The ability of signal sequences to drive Fab-phage display varies widely, and one signal sequence from murine binding immunoglobulin (mBiP) drove display levels that allowed efficient levels of Fab display.
[0273] In order to further improve the performance of the mBiP signal sequence, we used a phage-based codon optimization method because it has been shown that the function of eukaryotic signal sequences in bacteria can be greatly affected by codon selection (Humphreys et al., The Protein Expression and Purification, 20: 252-264 (2000)). A phage library was constructed in which the mBiP signal sequence was fused to the amino terminus of h4D5 Fab HC in a standard phagemid vector. The DNA sequence of the mBiP signal sequence was diversified in the third base of each codon after the first two methionines that only allow silent mutations. After 4 rounds of solid phase panning for immobilized Her2, each clone was selected and sequenced. We found that the consensus sequence of the selected clones strongly favors adenine or thymine, rather than guanine or cytosine, at randomized positions. This result is highlighted by the fact that 15 of the 17 codons in the wild-type mBiP sequence contain a guanine or cytosine at the third base position, but in the sorted libraries, each of the 17 codons contained an adenine or thymine at these positions 60-90% of the time. When tested in a phage ELISA, the optimized mBiP signal sequence drove h4D5 Fab display at levels comparable to the prokaryotic STII signal sequence, indicating that the mBiP signal sequence can replace the prokaryotic STII signal sequence for phage display and panning experiments without appreciable loss of performance.
[0274] Next, the ability of the mBiP signal sequence to support IgG expression and secretion in mammalian cells was evaluated. 1 Mammalian expression vectors of HC and LC (each with an mBiP signal sequence fused to the amino terminus) were co-transfected into suspended 293S cells and cultured for 5 days. The supernatant was then collected and purified by affinity chromatography. The yield of IgG was conventionally ~2.0 mg in a 30 mL culture, comparable to the yield obtained using the natural HC signal (VHS) in both chains (data not shown). Interestingly, the use of the wild-type versus codon-optimized form of the mBiP signal sequence had no discernible effect on the IgG expression level (data not shown). Gel filtration chromatography and mass spectrometry confirmed that the purified protein in the solution was >90% monomeric, and that the mBiP signal sequence was completely cut at the appropriate position on both HC and LC (data not shown). Since h4D5 is known to be a good expresser, we tested the performance of mBiP on an uncharacterized clone library arbitrarily selected from a phage panning experiment relative to VHS. In 30 mL suspension cultures, the average yield of these clones was ~1.0 mg, and no significant differences were observed between the two signal sequences ( Figure 2Aand B).
[0275] In summary, the mBiP mammalian secretion signal sequence can express IgG in mammalian cells at levels sufficient for screening and, once codons are optimized, can also drive strong Fab display on phage without compromising IgG expression levels.
[0276] Example 2: Expression of altered Fab fusions in prokaryotic and eukaryotic cells
[0277] To generate different Fab-fusion proteins in a host cell-dependent manner, we sought to exploit the natural process of intron splicing that occurs during mRNA processing in eukaryotic cells but not in prokaryotes. 1 The genomic sequence of the HC constant region contains three natural introns ( Figure 3A The first of these introns (intron 1) is located in the HC variable domain (V H ) and 384 base pairs between the hinge region. HC expression vectors containing intron 1 and an optimized splice donor sequence expressing fully spliced mRNA were evaluated by RT-PCR and sequencing transcripts, and when co-transfected with LC vectors, IgG 1 The expression was comparable to that of the vector without intron (Fig. 5).
[0278] To determine whether Fab fragments fused to a phage linker peptide embedded within the intron 1 sequence allow both phage display in bacteria and IgG expression in mammalian cells, respectively, the linker peptide ( Figure 3B ) or bacteriophage coat protein gene III ( Figure 3C ) was inserted into the h4D5 HC Intron 1 construct. The natural splice donor from intron 1 or 3 was removed immediately upstream of the linker peptide. When the HC-Linker.Intron 1 construct was co-expressed with h4D5 LC in mammalian cells, h4D5 IgG expression was approximately 40% (for the linker-containing intron) or 5% (for the gene-III-containing intron) of h4D5 IgG expression from a control construct without an intron ( Figure 4A ). RT-PCR showed that although the HC-linker mRNA portion was correctly spliced ( Figure 4B , middle band), significant amounts of mRNA or no splicing ( Figure 4B , upper strip) or at V H Incorrect splicing from a cryptic splice donor in the region ( Figure 4B , lower band). HC-gene-III mRNA is almost completely spliced from the cryptic splice donor. Silent mutations in the cryptic splice donor sequence only lead to the accumulation of unspliced mRNA (not shown).
[0279] Considering the failure of efficient splicing of introns when linker sequences are inserted, we compared the sequences of the natural splice donors with the known consensus sequences of mammalian mRNA splice donors (Stephens et al., J of Molecular Biology, 228: 1124-1136 (1992)). As shown in FIG5 , the sequence of the natural splice donors from hIgG 1 The natural splice donor of intron 1 differs from the consensus donor sequence at 3 of 8 positions. Substitutions at positions 1 and 5 were further analyzed because these positions are more conserved than position 8. A mutant splice donor (donor 1) was generated in which the bases at positions 1 and 5 were changed to match the consensus sequence ( Figure 5A ) and tested the ability of these modified donors to mediate splicing of synthetic introns in HC. The optimized splicing donors fully restored splicing of synthetic introns ( Figure 5B ), which was accompanied by an increase in h4D5 IgG expression to levels matching that of a control construct without an intron ( Figure 5C Improvements in splicing and IgG expression were observed regardless of whether the synthetic intron contained a linker peptide or gene-III, and regardless of whether the synthetic intron was based on hIgG1 intron 1 or intron 3.
[0280] Example 3: Generation of expression and secretion systems for prokaryotic and eukaryotic cells
[0281] For the generation of the dual vector plasmid, we used a pBR322-derived phagemid vector currently used for phage display, pRS. This bicistronic vector consists of the bacterial PhoA promoter driving expression of the antibody light chain cassette and its associated STII signal sequence, as well as the antibody heavy chain and its associated STII sequence. At the end of the light chain sequence, there is a gD epitope tag for detection of Fab displayed on the phage particle. In conventional phagemids, the heavy chain sequence consists only of the V region of hIgG. H and C H 1 domain, and it is fused with a utility peptide at the nucleotide level, such as a phage fusion protein, most commonly a gene encoding a phage coat protein pIII or a linker peptide. The 3' end of the light chain and heavy chain cassettes contains a lambda transcription termination sequence for terminating transcription in Escherichia coli. Since the vector produces light chain and heavy chain-pIII from a single mRNA transcript, there is no transcriptional regulatory element between the LC and HC sequences. The vector also contains a β-lactamase (bla) gene to confer ampicillin resistance, a pMB1 origin of replication in Escherichia coli, and an f1 origin for expressing pillus on the surface of bacteria, allowing infection by M13 phage. Another form of the vector also includes an SV40 origin of replication for episomal replication of plasmids in suitable mammalian cell strains.
[0282] For the construction of the initial binary vector (called "pDV.6.0"), we first inserted the mammalian CMV promoter from pRK (a mammalian expression vector for the expression of IgG and other proteins) upstream of the PhoA promoter driving the LC-HC cistron. At the end of the sequence encoding the LC antibody, we inserted an amber stop codon before the gD epitope tag, allowing the detection of the tagged LC on phage when displayed in an E. coli strain with an amber suppressor. The epitope tag is absent when the vector is expressed in mammalian cells. Thus, the LC cassette contains (in 5' to 3' order) a eukaryotic promoter, a bacterial promoter, a signal sequence, a sequence encoding the antibody light chain (LC), and an epitope tag (gD).
[0283] Next, between the HC and LC cassettes, we inserted a synthetic cassette containing (in 5' to 3' order) the SV40 mammalian polyadenylation / transcription termination signal, the lambda terminator sequence for transcription termination in E. coli , the CMV promoter, and the PhoA promoter.
[0284] Next, the SV40 mammalian polyadenylation / transcription termination signal and lambda terminator sequence are inserted after the HC cassette. The HC cassette contains the signal sequence and the sequence encoding the antibody heavy chain (HC).
[0285] To allow secretion of the fusion protein of interest in both prokaryotic and eukaryotic cells, we replaced the STII signal sequence preceding the LC and HC with the eukaryotic murine binding immunoglobulin (mBiP) signal sequence. Screening of several candidate signal sequences led us to the discovery that this signal sequence is functional in applications requiring prokaryotic expression (i.e., phage display) and / or eukaryotic expression (i.e., expression of IgG in mammalian cells), and that mBiP in these settings also worked as well as the individual signal sequences used prior to this work.
[0286] In order to allow the expression of Fab-phage in E. coli and IgG in mammalian cells, we have produced synthetic introns in the HC box. We have modified the natural introns from human IgG1 intron 1 or intron 3 to produce synthetic introns containing fusion proteins (gene-III) for display on phage particles. Immediately after the gene-III sequence separated by the stop codon, the genomic sequence of intron 1 (or intron 3) from human IgG1 is inserted to produce Fab HC-p3 fusions in E. coli. When expressed in E. coli, the placement of the natural splicing donor octanucleotide at the 5' flanking region of the synthetic intron requires two amino acid mutations (E212G and P213K, Kabat numbering) in the hinge region, and the mutations that produce optimized splicing donors have caused these residues to mutate into lysine. These mutations will not affect the level displayed on phage (not shown), and since the phage hinge region is removed during the splicing process, it is not present in the full-length IgG expressed in mammalian cells.
[0287] Alternatively, for the use of linker phage display, we generated a vector similar to the pDV6.0 vector described above with a different synthetic intron (referred to herein as pDV5.0, in Figure 7. Shown in ). The gene-III sequence is replaced by one of the two members of the leucine zipper pair (referred to herein as "joint") . In this synthetic intron, the joint peptide sequence is followed by the stop codon and the genomic sequence of intron 1 or 3. In this construct, we also inserted a separated bacterial expression cassette consisting of the gene-III fused to the homologous member of the leucine zipper pair. The separated bacterial expression cassette is introduced into the upstream of the LC CMV promoter and is controlled by the PhoA promoter, and the separated bacterial expression cassette contains the STII signal sequence to limit the joint-gene-III expression of Escherichia coli, and contains the lambda terminator immediately downstream. When expressed in Escherichia coli, the heavy chain and the light chain are assembled in the periplasm to form Fab, and the joint fused to the heavy chain is stably combined with the homologous joint on the pIII-joint protein. The assembled Fab-joint-pIII complex is packaged into the phage particle to obtain a phage displaying the target Fab. In addition, we have produced a conventionally mutated KO7 auxiliary phage, in which the partner joint is fused to the amino terminus of gene-III (joint-KO7). Infecting the Escherichia coli carrying pDV.5.0 with joint-KO7 causes pilli of all copies to be presented on the mature phagemid fused with the joint. As a result, pilli of all copies can be associated with Fab-joints, rather than just those pilli copies derived from pDV5. However, in some cases, when seeking extremely high affinity clones (e.g., in affinity maturation applications), it is desirable to display at a lower level. In this case, the mixture of joint-pIII (from pDV.5.0) and wild-type pilli (from KO7 auxiliary phage) displayed on phage particles was produced by infecting the Escherichia coli carrying pDV.5.0 with conventional KO7 auxiliary phage. In this case, since only a subset of all pilli libraries can be associated with joint-Fab, the display level obtained is lower than when using joint-KO7. This ability of regulating display level by selecting suitable auxiliary phage is a unique advantage of the present invention.
[0288] We evaluated the ability of pDV5.0 to express different IgGs in mammalian cells. HC and LC from 4 different human IgGs were subcloned into pDV5.0 and expressed in 293 cells. Somewhat surprisingly, the overall yield of pDV was consistently ~10-fold lower than that of the dual plasmid system. However, the yield was still on the order of ~0.1-0.4 mg per 30 mL culture ( Figure 6B ). This amount of material is sufficient for routine screening assays and can be easily increased to 0.1-1 L or more if larger amounts of material are required. By gel filtration chromatography, it was shown that >90% of the IgG in the solution was monomeric.
[0289] Example 4: Construction of a mutant helper phage M13KO7 (AMBER KO7)
[0290] To enhance the display of proteins fused to pill on M13 phage, we used site-directed mutagenesis to generate a mutant helper phage, Amber KO7. Amber KO7 has an amber codon introduced into the M13KO7 helper phage by site-directed mutagenesis. Figure 8 The nucleotide sequence of pill (nucleotides 1579 to 2853 of mutant helper phage Amber KO7) is shown in FIG.
[0291] To generate Amber KO7, helper phage M13KO7 was used to infect E. coli CJ236 strain (genotype dut - / ung - ), and the progeny virus particles were harvested to purify the ssDNA using an ssDNA purification kit (QIAGEN). The synthesized oligonucleotide (sequence 5'-GTGAATTATCACCGTCACCGACCTAGGCCATTTGGGAATTAGAGCCA-3') (SEQ ID NO: 23) was used to mutate gene-III in M13KO7 by oligonucleotide site-directed mutagenesis. The mutagenized DNA was used to transform Escherichia coli XL1-B1ue cells (Agilent Technologies) and inoculated on non-infected XL1-B1ue cell lawns on soft agar plates. Plaques were picked individually and the cells were cultured in LB medium containing 50 μg / ml kanamycin. Double-stranded replicative form (RF) DNA was extracted using a DNA microprep kit and sequenced to confirm the presence of the amber stop mutation. The homogeneity of the population was confirmed by AvrII restriction endonuclease digestion and agarose gel electrophoresis of RF DNA. All recombinant DNA procedures were performed as described in Sambrook, J. et al., A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratroy Press, Cold Spring Harbor, NY, 2001.
[0292] The levels of Fab displayed on phage particles produced using Amber KO7 were measured by phage ELISA. The antigen (Her2) was immobilized on an immunoplate and phage carrying anti-Her2 Fab was produced in XL1-B1ue cells using wild-type KO7 (WT KO7) or modified M13KO7 carrying an amber mutation in the pill (Amber KO7) helper phage. Binding was detected by incubation with mouse anti-M13-HRP conjugate and then measuring the TMB substrate OD at 450nm. The use of Amber KO7 resulted in higher display levels of low display phagemids (closed triangles) compared to the levels achieved by the same phagemid when WT KO7 was used for phage production (closed squares) ( Fig. 9 ). The Fab display levels using the low display phagemid of AmberKO7 (closed triangles) were also similar to the Fab display levels observed when the high display phagemid of WT KO7 was used (open diamonds) ( Fig. 9 ).
[0293] Example 5: Generation of expression and secretion systems for prokaryotic and eukaryotic cells to produce only unprocessed HC libraries And use of the system for phage panning
[0294] In addition to the direct and indirect fusion vectors (pDV5.0 and pDV6.0) described in Example 3 featuring prokaryotic and eukaryotic promoters on both the HC and LC, we also generated modified direct fusion binary vector constructs ( Fig.14 pDV.6.5 as shown in ), where the Fab LC is fused to the STII signal sequence and driven only by the bacterial PhoA promoter, while the Fab HC (containing the gene-III-synthetic intron and the hIgG Fc sequence for expression of full-length hIgG1 HC in mammalian cells) is driven by both the eukaryotic CMV promoter and the prokaryotic PhoA promoter. This construct was used to recapitulate the previously described synthetic human Fab library (Lee, et al., Journal of Molecular Biology, 340.1073-1093 (2004)), where diversity was introduced only into the HC. Expression of full-length IgG from this vector requires co-transfection of a mammalian expression vector encoding the LC.
[0295] Using oligonucleotide site-directed (Kunkel) mutagenesis and the "termination template" version of pDV.6.5, a phage display library was generated in which a stop codon (TAA) was placed in all three heavy chain CDRs. These stops were repaired during the mutagenesis reaction by a mixture of oligonucleotides annealed in the regions encoding CDRH1, H2 and H3, and codons were replaced with degenerate codons at randomized selected positions. The mutagenesis reaction was electroporated into XL1-Blue cells, and the culture was cultured in 2YT medium supplemented with Amber.KO7 helper phage, 50 μg / ml carbenicillin and 25 μg / ml kanamycin using a temperature conversion method (37°C for 4 hours, then 30°C for 36 hours). Phages were harvested from the culture medium by precipitation with PEG / NaCl. Each electroporation reaction used ~5 μg of DNA and produced 1×10 8 – 7×10 8 A transformant.
[0296] The panning of the untreated phage library produced in this vector was performed for human vascular endothelial growth factor (VEGF). For phage library sorting, the protein antigen was immobilized on the Maxisorp immunoplate, and the library was subjected to 4 to 5 rounds of binding selection. In alternating rounds, BSA or casein was alternatively used to block the plate wells. Random clones selected from the 3rd to 5th rounds were determined using phage ELISA to compare binding with the target antigen (VEGF) and an unrelated protein (Her2) for checking nonspecific binding. In brief, phage clones were cultured overnight in 1.6 mL of 2YT medium supplemented with Amber.KO7 helper phage (Example 4). The supernatant was combined with an immobilized antigen or an unrelated protein coated plate at room temperature for 1 hour. After washing, the bound phage was detected using an HRP-conjugated anti-M13 antibody (room temperature for 20 minutes) and then using TMB substrate detection. We isolated several clones that were ELISA positive for VEGF but not for an irrelevant control protein (Her2) ( Fig.10 - bar graph).
[0297] DNA from those clones showing specificity for VEGF were then used to express full-length IgG in small-scale 293 cell suspension cultures by co-transfection with a mammalian expression vector encoding a consensus LC. 1 mL of culture was transfected using Expifectamine or JetPEI according to the manufacturer's instructions and incubated at 37°C / 8% CO 2 Incubate for 5-7 days. Scale up transfections in 30 mL of 293 cells.
[0298] The culture supernatants were then screened for VEGF-binding IgG in an Fc capture assay on a BIAcore T100 instrument ( Fig.11 ). IgG supernatant from 1 mL of culture was used to screen for antigen binding. Anti-human Fc capture antibody was immobilized on a series of S CM5 sensor chips (~10,000RU). Supernatant was sequentially passed over flow cells 2, 3, and 4 (5 μL / min for 4 minutes) to allow capture of IgG (50-150RU) from the supernatant, followed by passing antigen (100-1000 nM) over the immobilized IgG (30 μL / min for 2 minutes) to measure binding response.
[0299] Sequencing of positive binders revealed 8 unique sequences ( Fig.12 The heavy chain CDR sequences are shown in Fig.12 ). Will be compared with phage ELISA ( Fig.10 ) and BiaCore data ( Fig.11 ) combined sequencing data ( Fig.12 ) was used to select a pool of 8 anti-VEGF clones for further analysis.
[0300] The expression of these eight clones was scaled up to 100 mL of Chinese hamster ovary (CHO) cell culture (see Fig.15 ), and the purified material was used to evaluate the ability of the anti-VEGF clone to block the binding of VEGF to one of its cognate receptors (VEGFR1) by receptor-blocking ELISA. Biotinylated hVEGF165 (2nM) was incubated with 3-fold serial dilutions of anti-VEGF antibody (200nM highest concentration) in PBS / 0.5% BSA / 0.05% Tween-20. After incubation at room temperature for 1-2 hours, the mixture was transferred to the VEGFR1-immobilized plate and incubated for 15 minutes. VEGFR-1-bound VEGF was then detected by incubation with streptavidin-HRP for 30 minutes, followed by development with TMB substrate, and the IC50 value was measured.
[0301] We identified a single antibody with ICs comparable to bevacizumab, a commercially available anti-VEGF antibody. 50 Equivalent IC 50 Clone (VEGF55) Fig.13 ). Thus, we were able to proceed directly from phage panning to IgG expression without the need for subcloning and to reduce the pool of clones to a single candidate.
[0302] In summary, this modified direct fusion binary vector (pDV.6.5) can be used in E. coli to construct a phage display library with randomized heavy chains and constant light chains, and when supplemented with a light chain expression vector, it can also be used in mammalian cells for subsequent expression of selected clones as natural IgG1 without subcloning. Since the mammalian CMV promoter is only present upstream of the HC, pDV expresses both Fab LC and Fab HC-pIII in E. coli, but only expresses hIgG1HC in mammalian cells. This vector can be used to select Fab fragments from an untreated synthetic Fab library that binds to multiple antigens, and then express full-length natural hIgG1 from selected clones in mammalian 293 and CHO cells by co-transfecting the modified direct fusion binary vector clones with a mammalian expression vector encoding a common LC. Native IgG1 obtained from expression experiments that were subjected to several assays, such as those obtained from a pool of 8 unique anti-VEGF clones that showed binding activity by ELISA and BIAcore, allowed us to sort individual candidates without the need to subclone HC sequences from the original phage vector clones in order to evaluate the candidates' in-solution properties, nonspecific binding, and biological activity in an IgG format.
[0303] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the illustration and example should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated by reference in their entirety.
Claims
1. A nucleic acid molecule encoding a first polypeptide comprising VH-HVR1, VH-HVR2 and VH-HVR3 of a variable heavy chain domain (VH) and / or a second polypeptide comprising VL-HVR1, VL-HVR2 and VL-HVR3 of a variable light chain domain (VL), and wherein the nucleic acid molecule further encodes a signal sequence that functions in both prokaryotes and eukaryotic cells, and the signal sequence is encoded by a nucleic acid sequence operably linked to the first and / or second polypeptide sequence, and wherein a full-length antibody is expressed from the first and / or second polypeptide of the nucleic acid molecule.
2. A nucleic acid molecule encoding a variable heavy chain (VH) domain and a variable light chain (VL) domain, and comprising a prokaryotic promoter and / or a eukaryotic promoter, the promoter being operably linked to the VH domain and / or VL domain to allow expression of the VH domain and / or VL domain in prokaryotic and eukaryotic cells, and wherein when expressed by eukaryotic cells, the VH domain and / or VL is linked to a utility peptide, and wherein the nucleic acid also encodes a signal sequence that functions in both prokaryotic and eukaryotic cells. A vector comprising the nucleic acid molecule according to claim 1 or 2.
4. A host cell transformed with the vector according to claim 3.
5. A method for producing an antibody, comprising culturing the host cell of claim 4 to allow the nucleic acid to be expressed.
6. A linker protein comprising a modification of at least one residue of the amino acid sequence of SEQ ID NO: 8, 9, 12, 13, 14 or 15.
7. A nucleic acid molecule encoding the adaptor protein of claim 6.
8. An isolated nucleic acid molecule encoding an mBIP polypeptide that functions in both prokaryotic and eukaryotic cells, the mBIP polypeptide comprising the amino acid sequence of SEQ ID NO:
3.
9. An isolated nucleic acid molecule encoding a polypeptide having an amino acid sequence having at least 85% amino acid sequence identity to an amino acid sequence selected from SEQ ID NO:
3.
10. A bacterial cell expressing an mBIP polypeptide or a variant thereof, wherein the mBIP polypeptide comprises the amino acid sequence of SEQ ID NO:
3.
11. A method for expressing an mBIP polypeptide or a variant thereof in both prokaryotic and eukaryotic cells, wherein the mBIP polypeptide comprises the amino acid sequence of SEQ ID NO:
3.
12. A polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, a variable heavy chain domain (VH) and a variable light chain domain (VL), wherein the VH domain is connected to the amino terminus of the VL domain.
13. A polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, a variable heavy chain domain (VH) and a variable light chain domain (VL), wherein the VH domain is connected to the carboxyl terminus of the VL domain.
14. A polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, and VH-HVR1, VH-HVR2 and VH-HVR3 of a variable heavy chain domain (VH).
15. A polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, and VL-HVR1, VL-HVR2 and VL-HVR3 of a variable light chain domain (VL).
16. A polypeptide comprising a signal sequence comprising the amino acid sequence of SEQ ID NO: 3 or a variant thereof, VH-HVR1, VH-HVR2 and VH-HVR3 of a variable heavy chain domain (VH), and VL-HVR1, VL-HVR2 and VL-HVR3 of a variable light chain domain (VL).
17. A nucleotide sequence of a helper phage comprising an amber mutation in pill, wherein the helper phage comprising the amber mutation enhances the display of a protein fused to pill on the phage.
